document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registranttable content gilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item reserve ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences truvada viread hepsera ambisome emtriva vistide letairis volibris ranexa cayston atripla register trademark belong bristolmyer squibb gilead sciences llc lexiscan register trademark belong astella llc macugen register trademark belong eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark belong hoffmannla roche inc report include trademark service mark trade name companiestable content annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption table content item business overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer life threaten disease worldwide headquarter foster city california operations north america europe australia date focus effort bring novel therapeutic treatment life threaten disease market continue seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquire cv therapeutics inc cv therapeutic publiclyheld biopharmaceutical company base palo alto california primarily focus discovery development commercialization small molecule drug treatment cardiovascular disease cv therapeutic market product ranexa ranolazine lexiscan regadenoson product candidate clinical development treatment cardiovascular metabolic pulmonary disease product truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat human immunodeficiency virus hiv infection adult fixeddose combination antihiv medication viread tenofovir disoproxil fumarate emtriva emtricitabine atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dose day treatment hiv infection adult atripla daily single tablet regimen hiv intend stand therapy combination antiretroviral fixeddose combination antihiv medication viread emtriva bristol myerssquibb company nonnucleoside reverse transcriptase inhibitor sustiva efavirenz viread oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult receive marketing approval viread treatment chronic hepatitis b licensed glaxosmithkline inc gsk right commercialize viread treatment chronic hepatitis b china emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva approve combination therapy treat hiv infection child hepsera adefovir dipivoxil oral formulation nucleotide analogue polymerase inhibitor dose day treat chronic hepatitis b license gsk right commercialize hepsera treatment chronic hepatitis b asia latin america certain territory ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand letairis ambrisentan endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class ii iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states table content ranexa indicate treatment chronic angina licensed menarini international operation luxembourg sa rights ranexa territory outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patient aids cayston aztreonam inhalation solution inhale antibiotic treatment improve respiratory system cystic fibrosis cf patient pseudomona aeruginosa p aeruginosa september receive conditional marketing approval cayston europe canada february receive marketing approval cayston united states follow table list aggregate product sale major product thousand total total total product product product sale sale sale antiviral product truvada atripla viread hepsera emtriva total antiviral product ambisome letairis ranexa total product sale item note consolidated financial statement include annual report total revenue geographic area royalty product tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states eyetech eyetech hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty eyetech base sale macugen worldwide lexiscan injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc exclusive right manufacture table content sell lexiscan united states subject obligation pay royalty base sale lexiscan united states market authorization application regadenoson mpi european union validate european medicine agency commercialization distribution international commercial sale operation marketing subsidiary australia austria belgium canada denmark finland france germany greece ireland italy netherlands new zealand norway portugal spain sweden switzerland turkey united kingdom united states product market commercial team andor conjunction party distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant party distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory united states commercial team promote truvada viread emtriva hepsera letairis ranexa promote atripla united states joint venture partner bristol myerssquibb company bm distribute truvada atripla viread emtriva hepsera vistide ranexa united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corp amerisourcebergen corp account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total revenue corporate partner astella promote sell distribute ambisome lexiscan united states cayston letairis distribute exclusively specialty pharmacy specialty pharmacy specialize dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute truvada viread emtriva hepsera ambisome asia australia europe latin america middle east new zealand commercial team party distributor corporate partner promote atripla jointly bms majority country europe responsible selling distribute product country limited number central eastern european country gilead bms party distributor sole promote sell distribute company agreement merck co inc merck promote distribute atripla country latin america asiapacific merck exist party distributor gsk promote sell distribute hepsera asia latin america certain territory plan promote sell distribute viread treatment chronic hepatitis b china rely corporate partner japan tobacco inc promote sell truvada viread emtriva japan corporate partner astella promote sell distribute ambisome canada dainippon sumitomo pharma co ltd responsible promotion distribution ambisome japan access develop world gilead access program establish certain hiv product available substantially reduce price country develop world develop system tiere pricing reflect economic status gross national incomegniper capita hiv prevalence approach allow price therapy base country ability pay example high hiv prevalence exist certain country country relatively high gni country move low price tier accommodate high burden disease table content support clinical study donation product help define good treatment strategy develop world country example november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection clinical study conduct mrc antiretroviral hiv therapy africa trial call dart development antiretroviral therapy study aim study clinical versus laboratory monitoring practice structure treatment interruption continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study work closely world health organization nongovernmental organization provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited setting support numerous clinical study investigate role ambisome treat visceral cutaneous leishmaniasis develop country collaboration organization drug neglect disease initiative mdecin san frontire enter number collaboration relate access product develop world include pharmachem technologies grand bahama ltd pharmachem pharmachem manufacture partner establish facility bahama manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla resource limited country cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen october enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution viread truvada treatment hiv infection certain develop world country include gilead access program november amend agreement aspen amend agreement aspen retain right manufacture distribute viread truvada treatment hiv infection develop world country aspen right purchase viread truvada unlabeled bottle distribution country right manufacture viread truvada active pharmaceutical ingredient purchase aspen supplier approve aspen grant right manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen require pay royalty net sale viread truvada royaltie net sale generic version tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination generic version emtricitabine manufacture distribute aspen generic license enter nonexclusive license agreement thirteen indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate treatment hiv infection low income country world include india low income country gilead access program agreement require generic manufacturer meet certain national international regulatory standard include technology transfer enable expeditious production large volume high quality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product merck co inc merck august enter agreement affiliate merck pursuant gilead merck provide atripla substantially reduce price hiv infect patient develop country africa caribbean latin america southeast asia agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement table content international partnership microbicide ipm conrad december enter agreement grant right ipm conrad cooperate agency agency international development commit improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resource limited country certain formulation tenofovir use topical microbicide prevent hiv infection competition product development program target number area include viral fungal respiratory cardiovascular disease commercially available product treatment disease company institution make substantial investment develop additional product treat disease product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development approximately brand hiv drug available united states product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sell joint venture establish november gsk pfizer focus hiv therapie hiv product compete directly product nrti class sell bms hiv product compete broadly hiv product abbott laboratories inc boehringer ingelheim gmbh merck pfizer roche tibotec therapeutic bmss videx ec didanosine ddi generic hiv product united states gsk retrovir zidovudine face generic competition united states result launch generic zidovudine bmss zerit stavudine face generic competition united states result launch generic stavudine date little impact generic didanosine zidovudine stavudine price hiv product price decrease hiv product result long term compound patent cover epivir lamivudine expire lamivudine market joint venture establish gsk pfizer competitive emtricitabine active pharmaceutical ingredient emtriva component truvada atripla certain party payor plan use entry generic lamivudine reason exert pricing pressure hiv product table content ambisome ambisome face strong competition current expect competitor competition current expect competitor erode revenue receive sale ambisome ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association hbv product hepatitis b virus hbv product hepsera viread face significant competition exist expect therapy treat patient chronic hepatitis b hbv product face competition baraclude entecavir oral nucleoside analogue develop bms launch united states tyzekasebivo telbivudine oral nucleoside analogue develop novartis pharmaceutical corporation novartis sale united states european union china hbv product compete epivirhbvzeffix lamivudine develop gsk collaboration shire pharmaceuticals group plc sell major country north south america europe asia hepsera viread treatment chronic hepatitis b compete establish immunomodulatory therapy include introna interferon alfab sell schere plough corporation major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment chronic hepatitis b letairis letairis compete directly tracleer bosentan sell actelion pharmaceutical inc actelion indirectly pah product united therapeutics corporation pfizer ranexa ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina vistide vistide compete number drug treat cytomegalovirus retinitis include cytovene iv cytovene ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc vitravene fomivirsen drug inject directly eye sell cibavision cayston cayston compete primarily tobi tobramycin inhalation solution usp inhale medication sell novartis treatment cf patient lung contain p aeruginosa tamiflu tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include table content amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trial macugen macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc lexiscan united states numerous market generic andor brand pharmacologic stress agent compete lexiscan clinical data inc develop apadenoson pharmacologic stress agent mpi currently phase clinical trial king pharmaceuticals inc develop binodenoson pharmacologic stress agent currently phase clinical trial product candidate compete lexiscan number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business find item note consolidated financial statement include annual report commercial collaboration currently number collaboration corporate partner govern manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bristolmyer squibb company bms december enter collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approve use united states july sell brand atripla bms structure collaboration joint venture form limited liability company call bristolmyers squibb gilead sciences llc term collaboration bms grant royalty free sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada sustiva respectively net selling price truvada change time relative net selling price sustiva bmss respective economic interest joint venture vary annually bms share marketing sale effort party provide equivalent sale force effort level agree annually bm daily operation joint venture govern primary joint committee form bms responsible accounting financial reporting tax table content report product distribution joint venture september bms amend joint venture collaboration agreement allow joint venture sell atripla canada agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product nonterminate party right continue sell atripla shortterm obligation pay royalty terminate party december enter collaboration bms set forth term condition bms commercialize atripla european union iceland liechtenstein norway switzerland bm party distributor act sell party country responsible thing receive process customer order warehouse product collect receivables handling return manufacture atripla coordinate primarily responsible distribution logistic general party share revenue outofpocket expense proportion net selling price truvada respect efavirenz respect bms agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european country cover agreement prior time party terminate agreement reason termination effective december nonterminate party right continue sell atripla obligate pay terminate party certain royalty year period follow effective date termination event nonterminate party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early f hoffmannla roche ltd hoffmannla roche inc roche september enter development license agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay percentage net sale roche generate tamiflu sale agreement receive upfront payment million entitle receive additional milestone payment million achievement certain development regulatory objective receive milestone payment october roche cash payment million relate reimbursement certain research preclinical development expense obligation prosecute maintain certain patent agreement november enter amendment supplement original agreement roche amendment eliminate cost good adjustment royalty calculation retroactive calendar year future calculation amendment provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis committee consist representative roche amendment option provide specialized sale force supplement roche marketing effort tamiflu exercise date agreement roche obligation pay royalty terminate countrybycountry basis patent provide exclusivity tamiflu country expire roche terminate agreement reason case right tamiflu revert party terminate agreement response material breach party glaxosmithkline inc gsk march sublicense gsk exclusive right market ambrisentan active pharmaceutical ingredient letairis market table content volibris territory outside united states pah territory outside united states license agreement receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million december receive million potential milestone payment addition receive royalty base net sale volibris gsk territory gsk option negotiate exclusive sublicense additional therapeutic use volibris gsk territory term license agreement agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis volibris united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development agreement gsk obligation pay royalty terminate countrybycountry basis early date generic equivalent sell country achieve certain percentage total prescription product plus generic equivalent fifteenth anniversary commercial launch country gsk terminate agreement reason termination right product revert party terminate agreement response material breach party research collaboration currently number collaboration corporate partner govern research development rd certain compound drug candidate follow research collaboration significant financial statement perspective significant ongoing collaboration activity exist japan tobacco inc japan tobacco march enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize product treatment hiv infection bear cost expense associate commercialization effort term agreement pay upfront license fee million obligate total potential milestone payment million achievement certain clinical regulatory commercial objective additionally obligate pay royalty base net sale territory market product december total milestone payment million agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party tibotec pharmaceutical tibotec july enter license collaboration agreement tibotec whollyowne subsidiary johnson johnson develop commercialize fixeddose combination truvada tibotecs nonnucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently phase clinical trial agreement tibotec grant exclusive license combination product administration adult daily oral dosage form worldwide exclude develop world country japan party restrict combine drug drug pay tibotec million tibotec development cost tmc require use commercially reasonable effort develop formulate combination product include table content completion bioequivalence study year end december record million reimbursable rd expense incur tibotec development tmc tibotec require use commercially reasonable effort develop tmc obtain approval united states europe manufacture combination product assume lead role registration distribution subject regulatory approval commercialization combination product license country tibotec right detail combination product license country option request distributor combination product limited number country price combination product expect sum price truvada price tmc purchase separately cost tmc purchase tibotec combination product approximate market price tmc specified percentage thirty percent party terminate agreement combination product withdraw market party materially breach agreement certain clinical regulatory condition meet terminate agreement united states canada expiration lasttoexpire patent tenofovir disoproxil fumarate united states terminate agreement country expiration lasttoexpire patent tenofovir disoproxil fumarate country european union tibotec terminate agreement united states canada expiration lasttoexpire patent tmc united states terminate agreement country expiration lasttoexpire patent tmc country european union research development addition enter collaboration company university medical research institution seek add exist portfolio product internal discovery clinical development program active inlicense product acquisition strategy acquisitions myogen inc corus pharma inc acquire navitas asset llcs asset relate cicletanine business evaluate potential treatment pah acquire cv therapeutic expand cardiovascular therapeutic area research scientist foster city palo alto san dimas california durham north carolina seattle washington engage discovery development new molecule technology hope lead new medicine novel formulation exist drug product development effort cover wide range medical condition include hivaid liver disease cardiovascular disease respiratory disease summary key product candidate correspond current stage development additional information development pipeline visit website wwwgileadcom product candidate description marketing application pende regadenoson market authorization application regadenoson use pharmacologic stress agent radionuclide mpi european union validate european medicine agency phase ambrisentan ambrisentan oral endothelin receptor antagonist evaluate treatment idiopathic pulmonary fibrosis ipf pulmonary hypertension secondary ipf table content product candidate description elvitegravir elvitegravir oral integrase inhibitor evaluate combination therapy hiv treatment experience patient combination truvada tmc combination tenofovir disoproxil fumarate emtricitabine tmc evaluation treatment hivaid treatmentnaive patient formulation work underway develop oncedaily fixeddose regiman compound phase aztreonam inhalation solution aztreonam inhalation solution evaluate treatment bronchiectasis cicletanine cicletanine oral agent evaluation treatment pah cobicistat gs cobicistat pharmacoenhancer evaluation boost agent certain hiv medicine antiretroviral fixeddose combination elvitegravir cobicistat oncedaily fixeddose quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate truvada emtricitabine evaluation treatment hivaid treatmentnave patient gs gs oral nonnucleoside polymerase inhibitor evaluate treatment hepatitis c gs gs inhale coformulation fosfomycin tobramycin evaluation treatment bacterial infection associate cf gs gs oral caspase inhibitor evaluation treatment hepatitis c nonalcoholic steatohepatitis prepare phase ranolazine ranolazine late sodium current inhibitor go evaluate treatment diastolic heart failure patient preserve ejection fraction phase gs gs ab adenosine antagonist evaluation treatment pulmonary disease gs gs novel protease inhibitor evaluate treatment hepatitis c gs gs oral epithelial sodium channel blocker design increase airway hydration patient pulmonary disease gs gs partial adenosine antagonist evaluation treatment diabete hypertriglyceridemia total rd expense million compare million million patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive table content product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product patent european patent product expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread ranexa lexiscan emtriva truvada atripla cayston supplementary protection certificate spc protection obtain certain european country confer auxiliary form patent exclusivity spc protection obtain certain european country confer auxiliary form patent exclusivity patent term extension apply spc apply marketing approval european union base european patent expiration date viread component truvada base european patent expiration date viread component atripla application pende patent cover active pharmaceutical ingredient truvada atripla viread emtriva hepsera letairis vistide lexiscan hold party acquire exclusive right patent agreement party patent cover ranolazine active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera application pende country asia include china relate specific form table content formulation hepsera asia major market therapy hepatitis b indication hepsera develop obtain patent certain product year obtain marketing approval product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license party technology obtain reasonable cost able obtain require license alternative technology unable develop commercialize product business adversely affect example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis addition actelion market tracleer apply patent claim method use era treatment ipf issue patent interfere effort commercialize era ambrisentan ipf patent application confidential period time patent issue know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful result operation adversely affect participation event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation examination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection example public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil tenofovir disoproxil fumarate active pharmaceutical ingredient truvada atripla viread pto grant request issue nonfinal rejection patent step common proceeding initiate reexamination process pto confirm patentability patent successful respond pto office action instance similar organization challenge patent foreign jurisdiction example april brazilian health ministry cite patent reexamination proceeding ground rejection request brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issue final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate file brazil file appeal patent authority respond question raise rejection july brazilian patent authority reject application high level appeal available brazilian patent authority file civil action brazilian federal court table content appeal action brazilian patent authority predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority court brazilian government likely purchase generic tenofovir disoproxil fumarate significantly reduce sale hiv product brazil brazilian government purchase approximately million hiv product anticipate purchase hiv product brazilian government similar level example patent office india initially allow claim cover tenofovir disoproxil tenofovir disoproxil fumarate indian civil procedure prior official grant allow application party file legal action protest decision grant patent august indian patent office announce decide action allow patent grant file appeal indian patent office application predict outcome proceeding unable successfully appeal decision appeal pursue indian court system ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unable successfully appeal negative decision indian patent office indian court competitor able continue sell generic tenofovir disoproxil fumarate reduce royalty receive indian generic license pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country africa asia include china permit enforcement patent party manufacturer able sell generic version product country approval process product food drug administration fda grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully example november receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit teva district court new york infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir patent protect viread january receive notice teva amend anda relate truvada atripla notice relate truvada teva challenge patent relate tenofovir additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir additional patent relate table content emtricitabine patent relate efavirenz expect file lawsuit teva infringement viread patent additional emtricitabine patent bms merck rights enforce defend patent relate efavirenz predict ultimate outcome action spend significant resource enforce patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada atripla viread united states substantially shorten patent cover product invalidate fda approve tevas request manufacture generic version product rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention manufacture raw material manufacturing strategy contract party manufacture majority solid dose product rely corporate partner manufacture certain product additionally manufacture facility san dimas california edmonton alberta canada cork ireland manufacture certain product active pharmaceutical ingredient clinical commercial use contract party manufacture certain product clinical commercial purpose include truvada atripla viread emtriva hepsera ranexa vistide cayston use multiple party contract manufacturer manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla emtricitabine active pharmaceutical ingredient emtriva active pharmaceutical ingredient truvada atripla rely single party manufacturer manufacture active pharmaceutical ingredient vistide ranexa cayston diluent cayston manufacture single manufacturer single site rely party contract manufacturers tablet capsulate product example use multiple party contract manufacturers tablet truvada atripla viread hepsera ranexa emtriva capsulation complete party contract manufacturer rely single party supplier tablet emtriva letairis manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astellas corporate partner lexiscan america responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device require administer cayston lung patient device single supplier single site san dimas facility manufacture fill package product manufacture ambisome cayston exclusively facility depend single supplier high quality cholesterol table content manufacture ambisome fill finish macugen exclusively facility san dimas manufacturing agreement eyetech pfizer eyetech currently provide pegaptanib sodium active pharmaceutical ingredient macugen fill package drug product truvada atripla viread emtriva hepsera ranexa finish form facility san dimas edmonton alberta facility carry process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product conduct chemical development activity improve exist commercial manufacturing process addition utilize site manufacture emtricitabine manufacture active pharmaceutical ingredient letairis hepsera exclusively edmonton site supplier qualify active pharmaceutical ingredient letairis fill package drug product truvada atripla viread emtriva cayston hepsera finish form facility cork ireland perform quality control testing final labeling package ambisome distribution product european union facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation party manufacturer corporate partner subject fda current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard similar regulation effect country manufacture operation subject routine inspection regulatory agency additionally party manufacturer corporate partner independent entity subject unique operational financial risk control party manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect believe technology use manufacture product proprietary product manufacture party contract manufacturer disclose necessary aspect technology enable manufacture product agreement party manufacturer intend restrict manufacturer reveal technology certain party manufacturer comply restriction addition party manufacturer develop technology relate work perform need manufacture product require enter additional agreement party manufacturer want use technology allow manufacturer use technology party manufacturer refuse allow use technology demand term use technology acceptable need access certain supply product manufacture product delivery material supplier interrupt reason unable purchase sufficient quantity raw material manufacture product unable ship certain product commercial supply supply product candidate development clinical trial addition product material utilize operation facility example manufacture ambisome cayston fill finish macugen exclusively facilities san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome cayston macugen meet market need problem single supplier depend negatively impact development commercialization effort table content future product continue consider develop additional manufacturing capability establish additional party supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future product ability conduct large scale clinical trial meet customer demand commercial product adversely affect seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent total revenue consist primarily tamiflu royalty affect seasonality royalty revenue recognize roche sale tamiflu impact severity flu season product delivery response hn influenza pandemic operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind application drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term table content involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum phase clinical trial adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review viread truvada atripla receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval table content country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country price reimbursement successful commercialization product depend availability governmental party payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority party payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price example significant portion sale majority product subject significant discount list price rebate obligation addition increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product revenue profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction significant change federal medicare system recent year united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare prescription drug program begin january benefit patient transition medicaid medicare long term impact medicare business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category party payer provide medicare coverage attempt negotiate price concession pharmaceutical manufacturer addition discussion take place federal level pass legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing increase pressure low prescription drug price limit drug access medicare enrollee medicare patient pay coinsurance influence product recommend physician select patient addition federal medicare proposal state medicaid drug payment change lower payment product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule president obamas administration united states congress healthcare reform priority propose reform extend coverage million uninsured americans reduce rate growth cost governmentsponsore healthcare program impend reform legislation congress include reduce coverage reimbursement product additional healthcare reform cost bear pharmaceutical biotechnology company include adverse impact business europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month table content reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product expect continue country attempt manage health care expenditure especially light global economic downturn new drug come market face significant price decrease product european country believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product health care fraud abuse law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law prohibit knowingly willingly present cause present payment party payer include medicare medicaid claim reimburse drug service false fraudulent claim item service provide claim claim medically unnecessary item service sale marketing activity subject scrutiny law violation fraud abuse law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid government allege convict violate law material adverse effect result operation august receive subpoena office inspector general department health human service request document development marketing sale ranexa cooperate continue cooperate relate governmental inquiry compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority file civil action brazilian federal court appeal action brazilian patent authority unable successfully appeal decision patent authority court brazilian government likely purchase generic tenofovir disoproxil fumarate significantly reduce sale hiv product brazil table content brazilian government purchase approximately million hiv product anticipate purchase hiv product brazilian government similar level addition concern cost availability tamiflu relate potential avian flu hn influenza pandemic generate international discussion compulsory licensing tamiflu patent example canadian government allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit party manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit party manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent party manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment health safety seek comply applicable statutory administrative requirement concern environmental quality worker health safety continue expenditure environmental compliance protection expenditure expect material effect capital expenditure result operation competitive position voluntarily assess greenhouse gas emission begin action reduce emission example establish employee commuter program evaluate energy efficiency building law regulation implement consideration mitigate effect climate change cause greenhouse gas emission example california air resources board process draft regulation meet state emission target base current information subject finalization propose regulation believe primary risk relate climate change risk increase energy cost energy intensive business anticipate subject cap trade system mitigation measure likely material capital expenditure result operation competitive position subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound rd activity eliminate risk accidental contamination injury material certain misuse accident involve material lead significant litigation fine penalty information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically table content mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale hiv product particularly truvada atripla unable maintain continue increase sale product result operation adversely affect currently dependent sale product treatment hiv infection particularly truvada atripla support exist operation hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development rd effort year end december truvada atripla product sale billion total revenue able sustain growth rate sale hiv product especially truvada atripla number reason include limited follow hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing market share affect portion pretax income derive royalty revenue recognize sale tamiflu roche sale tamiflu decrease pretax income disproportionately adversely affect f hoffmannla roche ltd hoffmannla roche inc roche market tamiflu worldwide treatment prevention influenza royaltypaye collaborative agreement recognize million royalty revenue year end december relate royalty receive sale table content tamiflu roche royalty revenue represent approximately total revenue represent pretax income period roche tamiflu sale unpredictable variability strong relationship global pandemic planning effort sale tamiflu increase sharply primarily result pandemic planning initiative worldwide sale tamiflu decrease royalty revenue decrease pretax income decrease disproportionately decrease material adversely impact operating result inability accurately estimate demand product sale fluctuation result inventory level hold wholesaler pharmacie non retail customer difficult accurately forecast sale cause earning fluctuate adversely affect financial result stock price approximately product sale united states wholesaler cardinal health inc mckesson corp amerisourcebergen corp wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesale location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order end user demand change example second quarter wholesaler increase inventory level atripla truvada inventory level viread decrease quarter wholesaler draw inventory inventory level atripla truvada end quarter consistent level hold quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state aids drug assistance program adap correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror purchasing pattern see retail sector example quarter observe large nonretail purchase small number state adap purchase centrally significant warehousing capacity believe purchase drive grant cycle federal adap fund current patient demand temper order associate product sale revenue earning second quarter organization deplete increase inventory level establish quarter expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future estimate future demand product consider shelf life inventory regularly review realizability inventory actual demand estimate demand require record inventory writedown adverse impact result operation stock price fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product market increase sale exist product able increase maintain total revenue continue expand rd effort example december announce phase clinical trial evaluate darusentan treatment resistant hypertension achieve coprimary efficacy endpoint result outcome decide discontinue development darusentan treatment resistant hypertension table content approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar face significant competition face significant competition large pharmaceutical biotechnology company substantially great resource addition competitor product operate field compete long hiv product compete primarily product joint venture establish glaxosmithkline inc gsk pfizer inc pfizer market fixeddose combination product compete truvada atripla compound patent cover epivir lamivudine expire lamivudine market joint venture establish gsk pfizer competitive emtricitabine active pharmaceutical ingredient emtriva component truvada atripla certain party payor plan use entry generic lamivudine reason exert pricing pressure hiv product hepsera viread treatment chronic hepatitis b compete primarily product produce gsk bristolmyer squibb company bms novartis pharmaceutical corporation novartis united states european union china ambisome compete primarily product produce merck co inc merck pfizer addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association letairis compete directly actelion pharmaceutical inc actelion indirectly pah product united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug betablocker calcium channel blocker longacte nitrate treatment chronic angina united states cayston competes product market novartis tamiflu compete product sell gsk generic competitor addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical table content company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product product letairis approve food drug administration fda june member class compound call endothelin receptor antagonist era pose specific risk include risk liver injury birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product example launch letairis case edema certain patient take letairis report information recently add product label negatively impact demand product safety resistance drug interaction issue arise market product include letairis sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial truvada atripla viread hepsera emtriva ambisome letairis ranexa cayston currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution september president bush sign law food drug administration amendment act significantly expand fdas authority include thing require sponsor market product conduct postapproval clinical study assess know risk signal risk identify unexpected risk table content mandate labeling change product point product lifecycle base new safety information require sponsor implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt example december announce phase clinical trial evaluate darusentan treatment resistant hypertension achieve coprimary efficacy endpoint result outcome decide discontinue development darusentan treatment resistant hypertension addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include elvitegravir novel hiv integrase inhibitor treatment hiv infection fixeddose regimen truvada tmc treatment hiv infection ambrisentan treatment idiopathic pulmonary fibrosis ipf currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance party contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform party cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact table content result operation adversely affect current potential future health care reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction significant change federal medicare system recent year united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare prescription drug program begin january benefit patient transition medicaid medicare long term impact medicare business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category party payer provide medicare coverage attempt negotiate price concession pharmaceutical manufacturer addition discussion take place federal level pass legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing increase pressure low prescription drug price limit drug access medicare enrollee medicare patient pay coinsurance influence product recommend physician select patient addition federal medicare proposal state medicaid drug payment change lower payment product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule president obamas administration united states congress healthcare reform priority propose reform extend coverage million uninsured americans reduce rate growth cost governmentsponsore healthcare program impend reform legislation congress include reduce coverage reimbursement product additional healthcare reform cost bear pharmaceutical biotechnology company include adverse impact business depend relationship company sale marketing performance revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada roche tamiflu gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor table content corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan south korea november enter agreement gsk provide gsk exclusive commercialization right registration responsibility viread treatment chronic hbv china success hepsera viread treatment chronic hbv territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera consequently gsk marketing strategy hepsera viread treatment chronic hbv influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera viread treatment chronic hbv net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera viread treatment chronic hbv territory potential revenue territory substantially reduce addition cayston letairis distribute party specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support cayston letairis devote resource necessary sell cayston letairis volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient party specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business cayston take patient specific inhalation device deliver drug lung patient commercial launch cayston ongoing distribution cayston entirely reliant manufacturer device example manufacturer encounter issue regulatory agency relate device unable supply sufficient quantity device time commercial launch follow commercial launch addition manufacturer able provide table content adequate warranty support device distribute patient respect distribution drug device patient reliant capability specialty pharmacy example distribution channel drug device complicated require coordination reimbursement approval process associate drug device similarly complex device manufacturer unable obtain reimbursement approval receive approval lowerthanexpecte price sale cayston adversely affect previously describe issue limit delay commercial launch cayston adversely affect financial result exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority party payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price example significant portion sale majority product subject significant discount list price rebate obligation addition increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product revenue profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product expect continue country attempt manage health care expenditure especially light global economic downturn new drug come market face significant price decrease product european country believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth expense associate clinical trial cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter fda andor regulatory agency require clinical testing originally anticipate uneven unexpected spending program cause operating result fluctuate quarter quarter stock price decline table content success depend significant degree ability protect patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent addition competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful result operation adversely affect event time time certain individual entity challenge patent example public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient truvada atripla viread pto grant request issue nonfinal rejection patent step common proceeding initiate reexamination process pto confirm patentability patent successful respond pto office action instance similar organization challenge patent foreign jurisdiction example april brazilian health ministry cite patent reexamination proceeding ground rejection request brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issue final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate file brazil file appeal patent authority respond question raise rejection july brazilian patent authority reject application high level appeal available brazilian patent authority file civil action brazilian federal court appeal action brazilian patent authority predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority court brazilian government likely purchase generic tenofovir disoproxil fumarate significantly reduce sale hiv product brazil example patent office india initially allow claim cover tenofovir disoproxil tenofovir disoproxil fumarate indian civil procedure prior official grant allow application party file legal action protest decision grant patent august indian patent office announce decide action allow patent grant file table content appeal indian patent office application predict outcome proceeding unable successfully appeal decision appeal pursue indian court system ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unable successfully appeal negative decision indian patent office indian court competitor able continue sell generic tenofovir disoproxil fumarate reduce royalty receive indian generic license brazilian government purchase approximately million hiv product anticipate purchase hiv product brazilian government similar level patent cover ranolazine active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapy hepatitis b indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension approval process product fda grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully example november receive notice teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir patent protect viread january receive notice teva amend anda relate truvada atripla notice relate truvada teva challenge patent relate tenofovir additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir additional patent relate emtricitabine patent relate efavirenz expect file lawsuit teva infringement viread patent additional emtricitabine patent bms merck rights enforce defend patent relate efavirenz predict ultimate outcome action spend significant resource enforce patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada atripla viread united states substantially shorten patent cover product invalidate fda approve tevas request manufacture generic version product table content success depend large ability operate infringe patent proprietary right party file lawsuit teva infringement emtricitabine patent infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation leap restrict distribution program design support letairis addition actelion market tracleer apply patent claim method use era treatment ipf issue patent interfere effort commercialize era ambrisentan treatment ipf furthermore use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation party manufacturer corporate partner subject fda current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard similar regulation effect country manufacture operation subject routine inspection regulatory agency additionally party manufacturer corporate partner independent entity subject unique operational financial risk control party manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect ability successfully manufacture commercialize cayston depend ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture party multiproduct manufacturing facility historically fda permit manufacture monobactam multiproduct manufacturing facility assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engage contract manufacturer singleproduct facility cayston fda prohibit manufacture mono bactam antibiotic like aztreonam multiproduct manufacturing facility future able procure singleproduct manufacturing facility timely manner adversely affect commercial supply cayston anticipate financial result attributable product able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product light economic downturn increase difficulty purchase certain raw material table content manufacturing process unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda file fda product candidate seek fda approval significant delay occur qualification new supplier require manufacturer qualified fda manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection fda follow initial approval result inspection fda determine equipment facility laboratory process comply applicable fda regulation condition product approval fda suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture ambisome cayston fill finish macugen exclusively facilities san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome cayston macugen meet market need cayston dependent different party singlesource supplier aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufacture single supplier single site second administer lung patient device single supplier single site diluent cayston manufacture single manufacturer single site disruption delay single supplier adversely affect ability produce cayston adequate quantity support commercial launch cayston sure alternative supplier identify timely manner addition depend single supplier high quality cholesterol manufacture ambisome depend single supplier active pharmaceutical ingredient vistide ranexa cayston tablete emtiva letairis astella llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort face credit risk european customer adversely affect result operation european product sale governmentowne support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice result continue result increase day sale outstanding average length time account receivable outstanding account receivable country total approximately million december million day past base contractual payment term historically receivable balance certain government own hospital accumulate period time subsequently settle large lump sum payment significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect example december million publiclyowned hospital greece event greek government default debt unable collect amount table content product revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country august agreement revenue adversely affect addition establish partnership thirteen indian generic manufacturer distribute highquality lowcost generic version tenofovir disoproxil fumarate develop world country include india generic version medication license reexporte united states europe market outside country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business country require grant compulsory license product face generic competition product number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority file civil action brazilian federal court appeal action brazilian patent authority unable successfully appeal decision patent authority court brazilian government likely purchase generic tenofovir disoproxil fumarate significantly reduce sale hiv product brazil brazilian government purchase approximately million hiv product anticipate purchase hiv product brazilian government similar level addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit party manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit party manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement table content patent party manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability costeffective product liability insurance decrease addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely impact addition negative publicity associate claim regardless merit decrease future demand product impair financial condition assumption determine selfinsurance level wrong materially impact business continually evaluate level selfinsurance base historical claim experience demographic factor severity factor actuarial assumption future occurrence claim differ assumption historical trend business financial result financial condition materially impact claim expense expensive litigation government investigation reduce earning november receive notice teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir patent protect viread january receive notice teva amend anda relate truvada atripla notice relate truvada teva challenge patent relate tenofovir additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir additional patent relate emtricitabine patent relate efavirenz expect file lawsuit teva infringement viread patent additional emtricitabine patent bms merck rights enforce defend patent relate efavirenz predict ultimate outcome action spend significant resource enforce patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada atripla viread united states substantially shorten patent cover product invalidate fda approve tevas request manufacture generic version product addition certain officer officer name defendant class action lawsuit allege violation federal security law august receive subpoena office inspector general department health human service request document development marketing sale ranexa cooperate continue cooperate relate governmental inquiry table content outcome lawsuit lawsuit brought investigation investigation bring inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate account stock option sharebase payment merger acquisition future level rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income income tax return audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period change accounting rule policy affect financial position result operation generally accept accounting principle relate implementation guideline interpretation highly complex involve subjective judgment change rule interpretation adoption new guidance application exist guidance change business significantly affect financial position result operation fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item b unresolved staff comment applicable item property corporate headquarters include principal office commercial administrative research development rd facility locate foster city california building lease facility foster city palo alto san dimas california house manufacturing warehousing rd activity addition lease facility durham north carolina boulder westminster colorado seattle washington house administrative rd activity international headquarter include commercial medical administrative facility locate lease london area united kingdom utilize manufacturing facility cork ireland primarily solid dose tablet manufacturing antiviral product product packaging activity lease facility dublin area ireland house distribution activity table content manufacture facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process lease additional facility house commercial medical administrative activity australia austria belgium canada france germany greece ireland italy netherlands portugal spain sweden switzerland turkey united kingdom believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding november receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic version atripla notice teva challenge emtricitabine patent file lawsuit district court new york teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir patent protect viread january receive notice teva amend anda relate truvada atripla notice relate truvada teva challenge patent relate tenofovir additional patent relate emtricitabine notice relate atripla teva challenge patent relate tenofovir additional patent relate emtricitabine patent relate efavirenz expect file lawsuit teva infringement viread patent additional emtricitabine patent bms merck rights enforce defend patent relate efavirenz predict ultimate outcome action spend significant resource enforce patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada atripla viread united states substantially shorten patent cover product invalidate fda approve tevas request manufacture generic version product information pertain certain legal proceeding find head legal proceeding item note consolidated financial statement include annual report incorporate reference item reserve table content ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception currently expect retain earning primarily use operation expansion business anticipate pay cash dividend near future effort return value stockholder minimize dilution stock issuance board directors board authorize program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean december complete share repurchase program january board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement repurchase plan expire january item note consolidated financial statement include annual report information stock repurchase program table content performance graph follow graph compare total stockholder return past year index standard poor stock index label sp index nasdaq biotechnology index label nbi index total return index assume reinvestment dividend pay company include index calculate december year composite member sp index nbi index intend use indice comparator stock performance purpose follow graph go forward composite member sp index require applicable regulation use index comparator believe nbi index relevant comparator compose peer company linesofbusiness similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december table content issuer purchase equity securities october board authorize program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated share repurchase transaction similar arrangement december complete share repurchase program january board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement repurchase plan expire january table summarize stock repurchase activity month end december thousands share amount maximum total number fair value share total number share purchase share average price publicly purchase purchase pay share announce programs program october october november november december december total difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation table content item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development total cost expense income loss operation provision income taxis net income loss attributable gilead net income loss share attributable gilead common stockholdersbasic share share calculationbasic net income loss share attributable gilead common stockholder dilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible senior note retain earning accumulate deficit total stockholder equity complete acquisition asset navita asset llc relate cicletanine business aggregate purchase price million allocate purchase inprocess research development iprd complete acquisition myogen inc aggregate purchase price billion billion allocate purchase iprd million allocate defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate goodwill million allocate net tangible asset acquire net asset corus pharma inc million million allocate purchase iprd million allocate net table content gilead sciences inc select consolidated financial datacontinued defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate net tangible asset million allocate assemble workforce recognize million royalty revenue relate resolution dispute f hoffmannla roche ltd hoffmannla roche inc record tax provision benefit million relate repatriation qualified foreign earning american job creation act ajca adopt guidance measuring recognize sharebase payment employee director include grant stock option begin january note consolidated financial statement annual report january adopt guidance convertible senior note retrospective basis guidance require bifurcate conversion option debt instrument classify conversion option equity accrete result discount debt additional interest expense expect life debt item note consolidated financial statement include annual report form k january adopt guidance joint venture bms retrospective basis result adopt guidance present noncontrolle interest consolidate statement income net loss attributable noncontrolle interest component consolidate net income retrospective basis item note consolidated financial statement include annual report complete acquisition cv therapeutics inc recognize consideration transfer billion primarily record intangible asset item note consolidated financial statement include annual report issue billion principal convertible senior note private placement enter uncollateralized million term loan agreement facilitate cash dividend distribution repatriation qualified foreign earning provision ajca table content item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer life threaten disease worldwide headquarter foster city california operations north america europe australia market product hivaid liver disease respiratory cardiovascularmetabolic therapeutic area product comprise truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b ambisome amphotericin b liposome injection treatment severe fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah ranexa ranolazine treatment chronic angina vistide cidofovir injection treatment cytomegalovirus infection cayston aztreonam inhalation solution treatment improve respiratory symptom cystic fibrosis cf patient pseudomona aeruginosa p aeruginosa f hoffmannla roche ltd hoffmannla roche inc roche market tamiflu oseltamivir phosphate treatment prevention influenza royaltypaye collaborative agreement eyetech inc markets macugen pegaptanib sodium injection united states europe treatment neovascular agerelate macular degeneration royaltypaye collaborative agreement glaxosmithkline inc gsk markets volibris ambrisentan outside united states treatment pah royaltypaye collaborative agreement menarini international operation luxembourg sa markets ranexa outside united states royaltypaye collaborative agreement astella llc markets lexiscan regadenoson injection united states use pharmacologic stress agent radionuclide myocardial perfusion image mpi royaltypaye collaborative agreement business highlight grow business significantly achieve record total revenue billion strengthen product portfolio pipeline program commercial achievement comprise continued rollout atripla european union include launch atripla france growth atripla truvada product sales united states canada make gain pah market letairis continue expansion sale marketing infrastructure grow product sale significantly continue strengthen worldwide organization infrastructure support expand international footprint business activity addition add ranexa product portfolio acquisition cv therapeutics inc cv therapeutic april february receive marketing approval food drug administration fda cayston treatment improve respiratory symptom cf patient p aeruginosa cayston conditionally approve europe canada september cayston deliver specific inhalation device develop pari pharma gmbh table content significant advance compound product candidate research development rd pipeline include hiv area january announce phase clinical study cobicistat gs pharmacoenhancer development boost agent certain hiv medicine complete singletablet fixeddose regiman contain elvitegravir cobicistat truvada treatmentnave patient meet primary objective noninferiority pende discussion fda expect initiate phase study middle study singletablet fixeddose regiman mention study cobicistat december complete enrollment phase study evaluate elvitegravir treatmentexperience patient addition collaboration tibotec pharmaceutical tibotec develop new oncedaily fixeddose combination contain truvada tibotecs investigational non nucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently phase clinical trial subject positive outcome study intend submit marketing application fixeddose combination truvada tmc united states europe second half liver disease area complete phase study gs caspase inhibitor license lg life sciences ltd development treatment hepatitis c nonalcoholic steatohepatitis expect present result second quarter continue phase b study gs treatment hepatitis c continue phase study gs nonnucleoside polymerase inhibitor evaluate treatment hepatitis c infection expect complete study second half cardiovascular metabolic area expand product candidate portfolio acquisition cv therapeutic anticipate commence patient enrollment phase study ranolazine treatment diastolic heart failure patient preserve ejection fraction second quarter continue phase study ambrisentan patient pulmonary hypertension secondary idiopathic pulmonary fibrosis ipf collaborate gsk develop clinical trial study combination therapy versus monotherapy firstline treatment set pah study ambition evaluate firstline combination use ambrisentan endothelin receptor antagonist era tadalafil pde inhibitor patient pah continue phase study cicletanine hydrochloride oral agent development treatment pah announce plan terminate development darusentan treatment resistant hypertension second phase study compound fail meet coprimary efficacy endpoint announce marketing authorization application regadenoson investigational pharmacologic stress agent radionuclide mpi validate european medicine agency emea follow validation marketing authorization application dossier distribute member committee medicinal product human use chmp formal review determine regadenoson safe efficacious pharmacologic stress agent human respiratory area continue phase study ambrisentan treatment ipf anticipate complete enrollment patient study end continue phase study gs inhale coformulation fosfomycin tobramycin treatment bacterial infection associate cf phase study aztreonam inhalation solution treatment bronchiectasis phase study gs oral epithelial sodium channel blocker design increase airway hydration treatment pulmonary disease acquisition cv therapeutic restructuring april complete acquisition cv therapeutic publiclyheld biopharmaceutical company base palo alto california primarily focus discovery development commercialization small molecule drug treatment cardiovascular metabolic pulmonary disease cv therapeutic table content market product product candidate clinical development treatment cardiovascular metabolic pulmonary disease believe acquisition provide opportunity expand cardiovascular therapeutic area adopt new business combination guidance recognize measure asset acquire liability assume noncontrolle interest acquiree apply cv therapeutic acquisition result recognize consideration transfer billion record million million intangible asset relate market product inprocess research development iprd project respectively constitute significant portion asset acquire cv therapeutic result operation cv therapeutic begin april acquisition date include consolidated financial statement year end december second quarter approve plan realize certain synergy cv therapeutic realign cardiovascular operation eliminate certain redundancy restructuring plan include consolidation realignment cardiovascular rd organization exit certain facility termination certain contractual obligation result restructure plan record million million sell general administrative sga expenses rd expense respectively primarily relate employee severance relocation termination benefit lease termination cost facilitiesrelate expense expect incur additional million bring total incur connection significant activity restructuring plan approximately million employee severance relocation termination benefit million facilitiesrelate expense financial highlight operating result year lead total product sale billion antiviral product sale truvada atripla viread hepsera emtriva increase billion billion key driver total product sale growth compare continue uptake atripla united states europe atripla contribute billion total antiviral product sale growth atripla product sale increase proportion overall product sale cause total product gross margin decrease primarily efavirenz component atripla sale zero gross margin truvada product sale comprise billion total antiviral product sale truvada product sale increase primarily continue sale volume growth united states europe foreign currency fluctuation unfavorable impact approximately million total revenue million pretax income compare royalty revenue recognize collaboration corporate partner million increase royalty revenue million increase royalty revenue primarily increase tamiflu sale roche relate pandemic planning initiative worldwide operating expense increase million compare reflect increase research clinical study activity development pipeline expand commercial activity worldwide high headcount infrastructure technologyrelate cost require support continue growth business cash cash equivalent marketable security increase million year drive primarily operate cash flow billion partially offset cash acquire cv therapeutic billion net cash cash equivalent marketable security acquire cv therapeutic million million repurchase approximately million share common stock open market purchase complete billion stock repurchase program authorize board directors board october table content outlook operating objective include increase market share commercial product continue strengthen pipeline internally develop andor externally inlicense purchase opportunity strengthen key alliance commercial standpoint number internal external initiative intend promote continue growth franchise hiv area expect favorable impact update atripla label include datum study support switch patient hiv regimen atripla revise department health human service treatment guideline recommend early treatment patient hiv extension ryan white treatment act provide stable funding aid drug assistance program united states hepatitis b virus hbv area continue support educational promotional activity focus asian community highlight need screen diagnose link patient care effort large hepatitis b field team united states cardiovascular area continue effort raise awareness gilead pah cardiology community believe help grow revenue letairis ranexa mindful conditions current macroeconomic environment affect ability achieve goal factor affect business include potential healthcare reform united states continue government pricing pressure internationally potential volatility foreign currency exchange rate continue monitor factor adjust business process mitigate risk business success experience help maintain build financially sound business model believe allow continue expand commercial collaborative rd activity maintain quality compliance continue grow business achieve great operational leverage remain focused profitable revenue growth prudent expense management believe enable solid execution operating objective critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition intangible asset allowance doubtful account prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer table content incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant judgment management government rebate estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program reimbursement portion retail price prescription fill cover program reduction settle company invoice directly chargeback wholesaler government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable pay rebate country outside united states date payment foreign government represent significant portion total government rebate government program united states estimate sale allowance base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate million million million respectively represent total gross product sale respectively deduct gross product sale believe methodology use estimate sale allowance government price reduction reasonable appropriate give current fact circumstance actual result differ base current information available actual government rebate claim period vary estimate record period december accrue government rebate million million respectively accrue liability allowance million million respectively record account receivable follow table summarize aggregate activity government rebate allowance accrue liability account balance deduct balance begin charge end year expense accrual year year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total intangible asset conjunction business combination complete record intangible asset primarily relate market product iprd project goodwill recognition measurement asset acquire liability assume business combination identifiable intangible asset table content relate market product iprd project measure respective fair value acquisition date believe fair value assign acquire intangible asset base reasonable estimate assumption give available fact circumstance acquisition date discount cash flow model value intangible asset model require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination goodwill intangible asset determine indefinite useful life amortize require test impairment annually test goodwill indefinitelive intangible asset impairment annual basis annual test aware event occur change circumstance indicate reduction fair value asset carry amount december million indefinitelive intangible asset consist million goodwill result business combination million intangible asset relate iprd project acquire cv therapeutic million iprd intangible asset acquire cv therapeutic million relate gs cvt product candidate phase clinical study treatment hypertriglyceridemia remain balance intangible asset relate iprd project represent inprocess project single project comprise significant portion total value estimate fair value iprd intangible asset acquire cv therapeutic determine income approach discount expect future cash flow present value estimate fair value intangible asset present value discount rate base estimate weightedaverage cost capital company profile substantially similar cv therapeutic comparable estimate internal rate return cv therapeutic operation represent rate market participant use value intangible asset compensate differ phase development project probabilityadjuste estimation expect future cash flow associate project determine present value expect future cash flow discount rate project cash flow iprd project base estimate assumption include note intangible asset finite useful life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable amortize intangible asset relate ranexa product acquire cv therapeutic estimate useful life amortization rate derive forecast future product sale ranexa product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast prospectively update rate amortize intangible asset relate ranexa increase future cost good sell record amortization expense amortize intangible asset relate lexiscan product acquire cv therapeutic estimate useful life cost good sell table content straightline basis give current lexiscan revenue consist royalty receive collaboration partner limit ongoing access visibility partner future sale forecast reasonable estimate amortization rate utilize forecasted product sale approach december million net unamortized finitelive intangible asset consist primarily intangible asset relate market product acquire cv therapeutic judgment existence impairment indicator base historical project future operating result extent manner use acquire asset legal regulatory factor event overall business strategy market economic trend event occur future cause conclude impairment indicator exist certain intangible asset impair financial condition result operation adversely impact allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account prepay royalty capitalize royalty prepay cost specifically related emtricitabine royalty pay emory university emory hiv indication base present value future royalty obligation expect pay emory assume certain expect future level product sale incorporate emtricitabine present value future royalty obligation derive weightedaverage cost capital review periodically expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty potential indicator impairment include launch significant product competitor significant deviation recognize product sale compare forecast product safety issue recall amortize prepay royalty base effective royalty rate derive forecast future hiv product sale incorporate emtricitabine product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast include introduction compete product competitor hiv market emtricitabine prospectively update royalty rate amortize prepay royalty increase future cost good sell record amortization expense december prepay royalty asset relate emtricitabine royalty pay emory million million respectively amortization expense relate prepay royalty asset million million million year end december respectively table content clinical trial accrual record accrual estimate clinical study cost clinical study perform party contract research organization cro cost significant component rd expense incur cro cost million million million respectively accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total clinical trial cost associate start activity trial patient enrollment extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management startup cost usually occur month contract execute milestone event drive nature remain clinical activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase clinical study year complex phase clinical study average length contract upper end range order provide longterm safety efficacy datum support commercial launch truvada atripla viread hepsera emtriva letairis ranexa material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record probable contract terminate december difference actual estimate activity level particular study material management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant rd expense future period tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment determined likely certain defer tax asset realized release related valuation allowance result credit goodwill approximately million income tax benefit approximately million million respectively future effective income tax rate affect factor change tax law regulation rate change interpretation exist law regulation impact accounting stockbase compensation change international organization change overall level income tax table content december total federal state foreign unrecognized tax benefit million million respectively include interest million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition reach agreement internal revenue service irs issue relate examination federal income tax return amend california income tax return base resolution certain tax position irs result reduce unrecognized tax benefit million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onward certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation remain open year income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period stockbase compensation measure sharebase payment employee director include grant stock option base relative fair value fair value award grant stock option plan employee stock purchase plan estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach nonveste stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual table content forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation additional paidin capital apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic year end december recognize stockbased compensation expense million million million respectively operating expense capitalize million million million respectively inventory december unrecognize stockbase compensation expense million relate nonveste stock option expect expense estimate weighted average period year management discuss development selection disclosure critical accounting policy audit committee board audit committee review disclosure present relate critical accounting policy result operation total revenue total revenue billion billion billion include total revenue product sale royalty revenue contract revenue product sale follow table summarize period period change product sale thousand change change antiviral product truvada atripla viread hepsera emtriva total antiviral product ambisome letairis ranexa total product sale total product sale increase compare compare primarily overall increase antiviral product sale include strong growth atripla sale continue growth truvada sale foreign currency denominate product sale experience net loss appreciation dollar approximately million compare net benefit depreciation dollar approximately million compare significant percentage product sale continue denominate foreign currency foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate table content antiviral product antiviral product sale increase compare compare drive primarily sale volume growth atripla truvada increase compare favorable foreign currency exchange impact truvada truvada sales increase compare drive primarily sale volume growth united states europe partially offset unfavorable foreign currency exchange impact truvada sale increase compare drive primarily sale volume growth united states europe favorable foreign currency exchange impact truvada sale account total antiviral product sale respectively atripla atripla sale increase compare drive primarily sale volume growth united states europe european growth benefit launch atripla france second quarter atripla sale increase compare drive primarily continue uptake atripla united states launch product european country atripla sale include efavirenz portion zero product gross margin efavirenz portion atripla sale approximately million million million respectively atripla sale account total antiviral product sale respectively antiviral product antiviral product sale include product sale viread hepsera emtriva decrease compare drive primarily sale volume decrease hepsera partially offset sale volume increase viread treatment patient chronic hepatitis b antiviral product sale increase compare drive primarily increase hepsera sale benefit favorable foreign currency exchange impact sale volume growth certain european country ambisome sale ambisome increase compare drive primarily sale volume growth certain european market partially offset unfavorable foreign currency exchange impact sale ambisome increase compare drive primarily favorable foreign currency exchange impact sale volume growth certain european market ambisome product sale united states canada relate solely sale ambisome astella pharma inc record manufacturing cost letairis sale letairis treatment pah increase compare drive primarily sale volume growth united states sales letairis increase compare drive primarily sale volume growth united states letairis launch june ranexa sale ranexa million period april date acquisition cv therapeutic december expect total product sale continue grow continue expand sale marketing effort table content royalty revenue follow table summarize period period change royalty revenue thousand change change royalty revenue significant source royalty revenue sale tamiflu roche royalty revenue million increase compare drive primarily recognition tamiflu royalty roche million compare tamiflu royalty roche million high tamiflu royalty increase tamiflu sale roche relate primarily pandemic planning initiative worldwide royalty revenue million decrease compare drive primarily recognition tamiflu royalty roche million compare tamiflu royalty roche million low tamiflu royalty primarily decrease roche sale relate pandemic planning initiative worldwide recognize royalty tamiflu sale roche quarter follow quarter tamiflu sell cost good sell product gross margin follow table summarize period period change product sale thousand cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin compare low product gross margin primarily high proportion atripla sale include efavirenz portion zero product gross margin amortization associate intangible asset acquire acquisition cv therapeutics product gross margin compare decrease product gross margin primarily high proportion atripla sale include efavirenz portion zero product gross margin impact change product geographic mix product sale high mix atripla product sale decrease overall product gross margin record atripla product sale benefit product gross margin truvada portion atripla sale efavirenz portion atripla sale carry zero product gross profit gross margin purchase efavirenz bristolmyers squibb company bms bmss net selling price efavirenz expect product gross margin lower compare primarily high proportion expect atripla sale table content research development expense follow table summarize period period change major component rd expense thousand change change research clinical development pharmaceutical development total research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform cro material supplies license fee overhead allocation consist support facilitiesrelate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost clinical trial pharmaceutical development expense consist cost product formulation chemical analysis rd expense increase million compare primarily increase compensation benefit expense million drive high headcount relate growth business rd expense reimbursement relate tibotec tmc collaboration million increase clinical study expense million increase compensation benefit expense drive severance termination benefit associate restructuring activity relate acquisition cv therapeutic rd expense increase million compare primarily increase clinical study expense million primarily antiviral cardiovascular area increase compensation benefit expense million primarily high headcount general significant collaboration payment like tibotec cause rd expense fluctuate period period expect rd expense increase level increase spending internal collaborative rd effort anticipate product candidate progress advanced clinical study add clinical development program pipeline sell general administrative expense follow table summarize period period change sga expense year thousand change change sell general administrative sga expense increase million compare primarily increase compensation benefit expense million drive high headcount relate growth business increase contract professional service expense million drive primarily expand sale marketing activity million relate certain contract termination cost increase compensation benefit expense drive severance termination benefit associate restructuring activity relate acquisition cv therapeutics sga expense increase million compare primarily increase compensation benefit expense million largely high headcount increase marketing table content promotional expense million support expand commercial operation increase consulting support service expense million relate growth business cost million associate certain employee terminationrelate dispute international operation expect sga expense increase level increase investment support growth hiv franchise year impact sale marketing activity ranexa commercialization cayston believe appropriate infrastructure support growth business purchase inprocess research development expense connection acquisition cicletanine asset navita asset llc record iprd expense million year end december consider acquisition material purchase disclosure relate purchase iprd connection acquisition myogen record purchase iprd expense billion year end december relate ambrisentan darusentan iprd project acquire purchase iprd expense represent estimate fair value myogen incomplete rd project reach technological feasibility alternative future use acquisition date expense acquisition respect ambrisentan june fda approve letairis treatment pah united states additionally april european commission grant collaboration partner gsk marketing authorization ambrisentan treatment pah market volibris gsk respect darusentan december announce plan terminate development darusentan treatment resistant hypertension second phase study compound fail meet coprimary efficacy endpoint connection acquisition corus pharma inc corus record purchase iprd expense million year end december relate aztreonam inhalation solution cf iprd project acquire purchase iprd expense represent estimate fair value coruss incomplete rd project reach technological feasibility alternative future use acquisition date expense acquisition february receive marketing approval fda cayston treatment improve respiratory symptom cf patient p aeruginosa cayston conditionally approve europe canada september interest income net record interest income net million million million respectively decrease compare primarily decrease interest income million drive reduction average yield investment portfolio result low interest rate partially offset increase net foreign currency exchange gain million decrease compare primarily increase cost relate hedging activity million net foreign currency exchange loss million decrease interest income million primarily low interest rate partially offset writedown certain security record interest expense january adopt guidance convertible senior note note convertible senior note note collectively note retrospective basis guidance require bifurcate conversion option debt instrument classify conversion option equity accrete result discount debt additional interest expense expect life debt result retrospective adoption guidance reflect additional interest expense table content million million respectively relate benefit income taxis million million respectively record additional interest expense million relate benefit income taxis million interest expense million million million respectively increase compare compare primarily effect accrete debt discount note additional interest expense expect life debt discuss provision income taxis provision income taxis million million million respectively effective tax rate differ federal statutory rate primarily tax credit resolution certain tax position tax authority certain operating earning nonus subsidiary consider indefinitely invest outside united states partially offset state taxis revaluation certain state tax asset relate integration cv therapeutic provide income taxis undistribute earning foreign operation intend permanently reinveste effective tax rate differ federal statutory rate primarily tax credit resolution certain tax position tax authority certain operating earning nonus subsidiary consider indefinitely invest outside united states partially offset state taxis effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states partially offset state taxis december total federal state foreign unrecognized tax benefit million million respectively include interest million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income reach agreement irs issue relate examination federal income tax return amend california income tax return base resolution certain tax position irs result reduce unrecognized tax benefit million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority table content liquidity capital resource follow table summarize cash cash equivalent marketable security work capital cash flow activity end year thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase million december increase primarily attributable net cash provide operation billion proceed issuance common stock employee stock plan million partially offset follow cash acquire cv therapeutic billion net cash cash equivalent marketable security acquire cv therapeutic million million repurchase common stock stock repurchase program million extinguish convertible senior note assume acquisition cv therapeutics cash cash equivalent marketable security total billion december increase million december increase primarily attributable net cash provide operation billion proceed issuance common stock employee stock plan million increase partially offset repurchase billion common stock stock repurchase program work capital work capital billion december decrease million work capital december decrease primarily attributable increase million account payable primarily purchase efavirenz estimate market value bms decrease million cash cash equivalent shortterm marketable security hold high proportion longterm marketable security december compare december decrease partially offset increase million account receivable net drive primarily increase product sale table content work capital december billion increase million december increase primarily attributable increase million inventory primarily purchase efavirenz estimate market value bms increase million account receivable net drive primarily increase product sale increase million cash cash equivalent shortterm marketable security increase partially offset million increase account payable primarily purchase efavirenz estimate market value bms cash provide operating activity cash provide operating activity billion primarily related net income billion adjust noncash item million stockbase compensation expense million amortization expense result adoption guidance joint venture bms january reclassify change noncontrolle interest cash provide operating activity cash financing activity cash provide operating activity billion primarily related net income billion adjust noncash item million tax benefit employee stock plan million stockbase compensation expense partially offset million excess tax benefit stock option exercise reclassify cash financing activity cash provide operating activity billion primarily related net income billion adjust noncash item million stockbase compensation expense million defer income taxis million tax benefit relate employee stock plan partially offset million net cash outflow relate change operate asset liability cash investing activity cash investing activity billion drive cash acquisition cv therapeutic billion net cash acquire net use million purchase marketable security million capital expenditure year capital expenditure related primarily expansion manufacturing capability upgrade facility spending computer laboratory equipment enterprise software accommodate continued business growth capital expenditure include purchase office building approximately acre land locate foster city california cash investing activity million drive primarily net use million purchase marketable security million capital expenditure year cash investing activity billion drive primarily net use billion purchase marketable security cash acquisition nycome limited million net cash acquire million capital expenditure year capital expenditure include construction new building foster city california headquarters december capital expenditure commitment million consist primarily enterprise software purchase commitment expect fulfill commitment fund generate operating cash flow table content cash financing activity cash financing activity billion drive primarily million repurchase common stock stock repurchase program million extinguish convertible senior note assume acquisition cv therapeutics cash outflow partially offset proceed million issuance common stock employee stock plan result adoption guidance joint venture bms january reclassify change noncontrolle interest cash provide operating activity cash financing activity discuss amend restate credit agreement whollyowne subsidiary gilead biopharmaceutics ireland corporation borrow aggregate billion revolving credit loan credit agreement include subfacility swingline loan letter credit loan credit agreement bear interest interest rate libor plus margin range percent percent base rate describe credit agreement april connection acquisition cv therapeutic borrow million credit agreement partially fund acquisition fully repay december credit agreement terminate december unpaid borrowing thereunder shall payable time reduce commitment prepay loan credit agreement penalty subject certain condition december approximately billion available draw credit agreement cash financing activity billion drive primarily billion repurchase common stock stock repurchase program cash outflow partially offset proceed million receive issuance common stock employee stock plan million excess tax benefit stock option exercise october board authorize program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean stock repurchase program repurchase share open market enter structured accelerated share repurchase transaction party describe february october enter accelerate share repurchase agreement financial institution repurchase common stock accelerate basis february transaction pay million settle initial purchase receive share common stock price share june termination agreement receive additional share common stock base average daily volume weightedaverage price common stock specify period predetermined discount share result total number share repurchase retire accelerate share repurchase agreement share average purchase price share october transaction pay million settle initial purchase receive share common stock price share march termination agreement receive additional share common stock base average daily volume weightedaverage price common stock specify period predetermined discount share result total number share repurchase retire accelerate share repurchase agreement share average purchase price share december complete share repurchase billion stock repurchase program january board authorize new program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean stock repurchase plan expire january cash financing activity million drive primarily million repurchase common stock stock repurchase program million pay table content remain amount term loan partially offset proceed issuance common stock employee stock plan million distribution noncontrolle interest million million excess tax benefit stock option exercise believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require assure available favorable term balance sheet arrangement balance sheet arrangement contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december thousands payment period contractual obligation total year year year year convertible senior note operate lease obligation capital commitment purchase obligation clinical trial total december outstanding principal billion note issue april december firm capital project commitment approximately million primarily relate enterprise software purchase commitment table content december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate item amount represent minimum purchase requirement actual purchase expect significantly exceed amount addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification tax authority certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority amount include longterm income taxis payable non current defer tax asset consolidate balance sheet include table recent accounting pronouncement june financial accounting standard board fasb issue amend standard determine consolidate variable interest entity accounting standard codification asc section amend standard eliminate mandatory quantitative approach determine variable interest give entity control financial interest variable interest entity favor qualitatively focus analysis require ongoing reassessment entity primarily beneficiary amend standard effective begin quarter consolidate joint venture bms primary beneficiary evaluate revised standard impact consolidate financial statement october fasb issue new standard revenue recognition agreement multiple deliverable new standard impact determination individual deliverable include multiple element arrangement treat separate unit account additionally new standard modify manner transaction consideration allocate separately identify deliverable long permit residual method allocate arrangement consideration new standard effective begin quarter early adoption permit evaluate new standard material impact consolidate financial statement item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency table content significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business significant percentage product sale denominate foreign currency enter foreign currency exchange forward option contract partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge follow table summarize notional amount weightedaverage currency exchange rate fair value open foreign currency exchange forward contract december foreign currency exchange option contract outstanding december contract maturity month weightedaverage rate state term dollar foreign currency fair value represent estimate settlement amount december notional amount fair value dollar thousand foreign currency exchange forward contract weight average notional settlement currency price fair value euro british pound canadian dollar australian dollar swiss franc danish krone swedish krone norwegian krone new zealand dollar turkish lira total total notional billion total fair value relate net liability million open foreign currency exchange forward contract december compare total notional billion total fair value relate net asset million open foreign currency exchange forward option contract december interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return table content follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december dollar thousand year end december total fair value december total asset availableforsale debt security average interest rate liability convertible senior note average interest rate april issue note private placement pursuant rule securities act amend note issue par bear interest rate note note respectively convert share common stock subject certain circumstance credit risk portion marketable security consist auction rate security begin observe fail auction auction rate security underlie asset comprise student loan december hold approximately million auction rate security availablefor sale longterm marketable security underlie asset comprise student loan auction rate security comprise approximately total cash cash equivalent marketable security december auction rate security include subject fail auction currently rate aaa consistent high quality rating require investment policy support federal government federal family education loan program overcollateralize auction rate security reset seven day maturity date range annual interest rate range december auction rate security continue earn interest auction continue fail security invest unable liquidate auction rate security par need desire access fund invest security base total cash marketable security position expect operating cash flow access fund credit facility believe able hold security recovery auction market relate security final maturity result anticipate current illiquidity auction rate security material effect cash requirement work capital light volatility development see financial market continue review cash equivalent marketable security carefully strive invest prudently believe maintain primary goal investment policy safety preservation principal diversification risk liquidity protect risk credit market allow continue meet operate cash flow requirement execute strategic opportunity acquisition cv therapeutics account receivable balance december billion compare billion december growth account receivable balance primarily high product sale antiviral product united states europe european product sale governmentowne support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice result continue result increase day sale outstanding average length time account receivable outstanding turn increase credit risk relate certain customer sale customer country europe tend pay relatively slowly increase continue increase december table content account receivable greece italy portugal spain total million million day past base contractual payment term date experience significant loss respect collection account receivable believe account receivable net allowance reflect consolidated balance sheet collectible item financial statement supplementary datum financial statement require item set forth begin annual report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report effectiveness internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting table content report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date march express unqualified opinion thereon ernst young llp palo alto california march table content item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee qualification nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service table content iv item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document agreement plan merger registrant apex merger sub inc cv therapeutics inc date march stockholder agreement registrant louis g lange date march restate certificate incorporation registrant amend certificate designation series junior participate prefer stock registrant certificate amendment certificate designation series junior participate prefer stock registrant amend restate bylaw registrant amend restate october reference exhibit exhibit exhibit exhibit amend restate right agreement registrant chasemellon shareholder services llc date october amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date october second amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april table content exhibit exhibit footnote number description document confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire amend restate credit agreement registrant gilead biopharmaceutics ireland corporation lender party thereto bank america na administrative agent swing line lender lc issuer date december parent guaranty agreement date december registrant master confirmation registrant citibank na supplemental confirmation date october gilead sciences inc stock option plan amend january form option agreement stock option plan gilead sciences inc nonemployee directors stock option plan amend january form option agreement gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amend form employee stock option agreement equity incentive plan grant prior february form employee stock option agreement equity incentive plan grant february april form employee stock option agreement equity incentive plan grant january form employee stock option agreement equity incentive plan grant commence february form nonemployee director stock option agreement equity incentive plan grant prior form nonemployee director option agreement equity incentive plan initial grant form nonemployee director option agreement equity incentive plan annual grant form nonemployee director option agreement equity incentive plan annual grant commencing form restrict stock agreement equity incentive plan annual grant nonemployee director commence form restrict stock agreement equity incentive plan annual grant certain nonemployee director table content exhibit exhibit footnote number description document form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan grant form restrict stock unit issuance agreement equity incentive plan grant prior form restrict stock unit issuance agreement equity incentive plan grant commencing gilead sciences inc employee stock purchase plan amend restate november gilead sciences inc international employee stock purchase plan adopt november gilead sciences inc defer compensation planbasic plan document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan gilead sciences inc defer compensation plan amend restate october gilead sciences inc severance plan amend january gilead sciences inc corporate bonus plan gilead sciences inc code section bonus plan base salary name executive officer offer letter date april registrant robin washington form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date september commercialization agreement gilead sciences limited bristolmyers squibb company date december amendment agreement date october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega follow exhibit license agreement date december registrant iocb rega license agreement license agreement date october registrant iocb rega october license agreement license agreement date december registrant iocb rega december license agreement table content exhibit exhibit footnote number description document amendment agreement registrant iocbrega date december amend license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant date august amend october license agreement december license agreement development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september amendment supplement date november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july license agreement japan tobacco inc registrant date march license agreement registrant successor myogen inc abbott deutschland holding gmbh date october license agreement registrant successor myogen inc abbott laboratories date june license agreement registrant successor cv therapeutics inc syntex usa inc date march amendment license agreement registrant successor cv therapeutics inc syntex usa inc date july amendment license agreement registrant successor cv therapeutics inc syntex usa inc date november amendment collaboration license agreement registrant successor cv therapeutics inc roche palo alto llc date june license collaboration agreement registrant gilead sciences limited tibotec pharmaceutical date july master clinical commercial supply agreement gilead world market limited registrant patheon inc date january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date december table content exhibit exhibit footnote number description document tenofovir disoproxil fumarate manufacture supply agreement registrant ampac fine chemical llc date march restate amend toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh date november emtricitabine manufacturing supply agreement gilead sciences limited degussa ag date june purchase sale agreement escrow instruction electronics imaging inc registrant date october subsidiary registrant consent independent register public accounting firm power attorney reference signature certification chief executive officer require rule aa rule da securities exchange act amend certification chief financial officer require rule aa rule da securities exchange act amend certification chief executive officer chief financial officer require rule ab rule db section chapter title united states code usc follow material registrant annual report year end december format extensible business report language xbrl include consolidated balance sheet december ii consolidated statement income year end december iii consolidated statement cash flow year end december iv note consolidated financial statement tag block text file exhibit registrant current report form k file march incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file november incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file june incorporate reference file exhibit registrant current report form k file april incorporate reference table content file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form ka file february incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant registration statement form file december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference information include registrant current report form k file february incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference table content file exhibit registrant annual report fiscal year end december incorporate reference file exhibit triangle pharmaceutical inc quarterly report form qa file november incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference file exhibit cv therapeutic inc registration statement form amend originally file april incorporate reference file exhibit cv therapeutic inc quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form k file august incorporate reference management contract compensatory plan arrangement certification accompanie relate deem file security exchange commission incorporate reference file registrant security act amend securities exchange act amend date irrespective general incorporation language contain filing xbrl information furnish file registration statement prospectus purpose section securities act amend deem file purpose section security exchange act amend subject liability section certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary securities exchange commission mark pursuant registrant application request confidential treatment rule b securities exchange act amend table content gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement table content report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement company change method accounting convertible senior note settle cash conversion method accounting presentation noncontrolle interest method accounting business combination effective january audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date march express unqualified opinion thereon ernst young llp palo alto california march table content gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net noncurrent portion prepay royalty noncurrent defer tax asset longterm marketable security intangible asset noncurrent asset total asset liability stockholder equity current liability account payable accrue government rebate accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion longterm obligation total current liability longterm defer revenue convertible senior note net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note table content gilead sciences inc consolidated statement income thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development total cost expense income operation interest income net interest expense income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute accompany note table content gilead sciences inc consolidated statement stockholders equity thousand gilead stockholder equity common stock accumulate retain additional earning total paidin comprehensive accumulate noncontrolle stockholder share capital income loss deficit interest equity balance december adoption new accounting guidance income taxis distribution noncontrolle interest net income loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction repurchase common stock balance december distribution noncontrolle interest net income loss unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction repurchase common stock balance december distribution noncontrolle interest net income loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction assumption stock option connection acquisition repurchase common stock balance december accompany note table content gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization purchase inprocess research development expense stockbase compensation expense excess tax benefit stockbase compensation tax benefit employee stock plan defer income taxis noncash transaction change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security acquisition net cash acquire purchase nonmarketable equity security capital expenditure net cash investing activity financing activity proceed issuance common stock proceed credit facility repayment credit facility repurchase common stock extinguishment longterm debt repayment longterm debt obligation excess tax benefit stockbase compensation distribution noncontrolle interest net cash financing activity effect exchange rate change cash net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay income taxis pay accompany note table content gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer life threaten disease worldwide headquarter foster city california operations north america europe australia currently market truvada emtricitabinetenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b ambisome amphotericin b liposome injection treatment severe fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah ranexa ranolazine treatment chronic angina vistide cidofovir injection treatment cytomegalovirus infection cayston aztreonam inhalation solution treatment improve respiratory symptom cystic fibrosis cf patient pseudomona aeruginosa p aeruginosa f hoffmannla roche ltd hoffmannla roche inc roche market tamiflu oseltamivir phosphate treatment prevention influenza royaltypaye collaborative agreement osi pharmaceuticals inc markets macugen pegaptanib sodium injection united states europe treatment neovascular agerelate macular degeneration royaltypaye collaborative agreement glaxosmithkline inc gsk markets volibris ambrisentan outside united states treatment pah royaltypaye collaborative agreement menarini international operation luxembourg sa menarini market ranexa outside united states royaltypaye collaborative agreement astella llc markets lexiscan regadenoson injection united states use pharmacologic stress agent radionuclide myocardial perfusion image mpi royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary joint ventures bristol myers squibb company bms primary beneficiary record noncontrolle interest consolidated financial statement reflect bmss interest joint venture significant intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition applicable reporting period fasb accounting standard codification july adopt financial accounting standard board fasb accounting standard codification asc fasb asc source authoritative generally accept accounting principle gaap recognize fasb apply nongovernmental entity effective interim period fiscal year end september result majority historically issue accounting pronouncement supersede fasb asc convertible senior note january adopt guidance convertible senior note note convertible senior note note collectively note retrospective basis guidance require bifurcate conversion option debt instrument classify conversion option table content gilead sciences inc note consolidated financial statementscontinue equity accrete result discount debt additional interest expense expect life debt result retrospective adoption guidance reflect additional interest expense million million respectively relate benefit income taxis million million respectively decrease net income share attributable gilead common stockholder dilute basis respectively year end december record additional interest expense million relate benefit income taxis million decrease net income share attributable gilead common stockholder dilute basis approximately year end december addition retrospective adoption guidance decrease defer tax asset debt issuance cost include asset aggregate million decrease convertible senior note net include longterm liability million increase total stockholder equity million charge million retain earning consolidate balance sheet december note additional information noncontrolle interest january adopt guidance joint venture bms retrospective basis guidance establishe accounting reporting standard ownership interest subsidiary hold party parent consolidate net income loss attributable parent noncontrolle interest change parent ownership interest valuation retain noncontrolle equity investment subsidiary deconsolidate guidance establish additional reporting requirement identify distinguish ownership interest parent interest noncontrolle owner guidance effective interim period fiscal year begin december require retrospective application period present result retrospective adoption guidance reclassify noncontrolle interest minority interest liability stockholder equity consolidate balance sheet adoption guidance result reclassification change noncontrolle interest net cash provide operating activity net cash financing activity consolidate statement cash flow present noncontrolle interest consolidate statement income net loss attributable noncontrolle interest component consolidate net income retrospective basis significant accounting policy estimate judgment preparation consolidate financial statement conformity gaap require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate estimate include critical accounting policy estimate related revenue recognition intangible asset allowance doubtful account prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid table content gilead sciences inc note consolidated financial statementscontinue reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale government rebate estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return permit return product damage defective receive customer case product sell unite state certain international country product expired accept return product expire month prior expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenues royalty revenue sale lexiscan ambisome astella pharma inc astella recognize month follow month correspond sale occur royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur contract revenue revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation table content gilead sciences inc note consolidated financial statementscontinue complete accordance specific term gilead obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement income research development expense major component research development rd expense consist personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development expense consist cost product formulation chemical analysis charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform party cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study reflect level effort actually incur cro material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record probable contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option equivalent consist primarily performance share assume exercise warrant relate note determine treasury stock method table content gilead sciences inc note consolidated financial statementscontinue principal note settle cash conversion spread relate note include calculation dilute net income share attributable gilead common stockholder common stock result assume settlement conversion spread note dilutive effect average market price common stock period exceed conversion price note note respectively year end average market price common stock exceed conversion price note dilutive effect include table warrant relate note note dilutive effect average market price common stock period exceed warrant exercise price respectively average market price common stock year end december exceed warrant exercise price relate note stock option purchase approximately million million million weightedaverage share common stock outstanding year end december respectively include computation dilute net income share attributable gilead common stockholder option exercise price great average market price common stock period effect antidilutive follow table reconciliation numerator denominator calculation basic diluted net income share attributable gilead common stockholder thousand year end december numerator net income attributable gilead denominator weightedaverage share common stock outstanding calculation basic net income share attributable gilead common stockholder effect dilutive security stock option equivalent conversion spread relate note conversion spread relate note weightedaverage share common stock outstanding calculation dilute net income share attributable gilead common stockholder stockbase compensation january adopt guidance sharebase payment employee director include grant stock option guidance require sharebased payment employee recognize consolidated statement income base fair value guidance require benefit tax deduction excess recognize compensation cost report consolidated statement cash flow financing activity operating activity apply modify prospective method require compensation expense record vest nonveste stock option stockbase award begin quarter adoption addition calculate pool excess tax benefit available additional paidin capital apic accordance provision guidance table content gilead sciences inc note consolidated financial statementscontinue cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent enter overnight repurchase agreement repos purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security include auction rate security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review security indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe certain country payment typically slow primarily greece italy portugal spain aggregate account receivable balance significant case slow payment practice country reflect pace governmental entity reimburse customer turn increase financial risk relate table content gilead sciences inc note consolidated financial statementscontinue certain customer sale customer country europe tend pay relatively slowly increase continue increase december aggregate account receivable greece italy portugal spain total million million day past base contractual payment term date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government rebate program cash discount prompt payment doubtful account sale return estimate wholesaler chargeback government rebate cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize prepay royalty prepay royalty capitalize cost initially equivalent present value future royalty obligation expect pay licensor expect future level product sale incorporate related technology review periodically expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale incorporate related technology review effective royalty rate annually prospectively adjust effective rate base significant new fact circumstance arise review prepay royalty primarily comprise emtricitabine royalty pay emory university emory hiv indication royalty pharma purchase royalty interest own emory term transaction royalty pharma pay respectively total table content gilead sciences inc note consolidated financial statementscontinue purchase price million emory exchange elimination emtricitabine royalty emory worldwide net sale product contain emtricitabine result transaction capitalize prepaid royalty share million purchase price million december unamortized prepay royalty asset million million respectively million million million amortize cost good sell respectively property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost million million consolidated balance sheet december respectively leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset primarily relate market product purchase inprocess research development iprd project acquisition cv therapeutics inc cv therapeutics april measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful life test goodwill indefinitelive intangible asset impairment annual basis annual test aware event occur change circumstance indicate reduction fair value asset carry amount intangible asset finite useful life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable amortize intangible asset relate ranexa product acquire cv therapeutic estimate useful life amortization rate derive forecast future product sale ranexa product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast prospectively update rate amortize intangible asset relate ranexa increase future cost good sell record amortization expense amortize intangible asset relate lexiscan table content gilead sciences inc note consolidated financial statementscontinue product acquire cv therapeutic estimate useful life cost good sell straightline basis give current lexiscan revenue consist royalty receive collaboration partner limit ongoing access visibility partner future sale forecast reasonable estimate amortization rate utilize forecasted product sale approach impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate income produce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income record accumulate comprehensive income loss separate component stockholder equity net foreign currency exchange transaction gain loss include interest income net consolidated statement income net transaction gain loss total million million million respectively hedge certain foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract foreign currency exchange option contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time limit risk counterpartie contract unable perform transact major bank monitor closely context current market condition limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction hedge net investment foreign subsidiary fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable foreign currency exchange forward option contract account payable longterm debt cash cash equivalent marketable security foreign currency exchange contract hedge account receivable forecast sale report respective fair value consolidate balance sheet carry value fair value note billion billion respectively table content gilead sciences inc note consolidated financial statementscontinue december carry value fair value note billion billion respectively december fair value note base quote market value remain financial instrument report consolidated balance sheet amount approximate current fair value income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate account stock option sharebase payment merger acquisition future level rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate net income record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period recent accounting pronouncement june fasb issue amend standard determine consolidate variable interest entity asc section amend standard eliminate mandatory quantitative approach determine variable interest give entity control financial interest variable interest entity favor qualitatively focus analysis require ongoing reassessment entity primarily beneficiary amend standard effective begin quarter consolidate joint venture bms primary beneficiary evaluate revised standard impact consolidate financial statement october fasb issue new standard revenue recognition agreement multiple deliverable new standard impact determination individual deliverable include multiple element arrangement treat separate unit account additionally new standard modify manner transaction consideration allocate separately identify deliverable long permit residual method allocate arrangement consideration new standard effective begin quarter early adoption permit evaluate new standard material impact consolidate financial statement fair value measurement january adopt guidance fair value measurement prospective basis financial asset liability nonfinancial asset liability recognize disclose table content gilead sciences inc note consolidated financial statementscontinue fair value recur basis guidance define fair value establishe framework measure fair value expand disclosure requirement fair value measurement guidance effective fiscal year begin november financial asset liability nonfinancial asset liability recognize disclose fair value recur basis financial statement effective fiscal year begin november nonfinancial asset liability january adopt provision guidance prospective basis non financial asset liability recognize disclose fair value recur basis adoption guidance effect consolidate net income year end december fair value guidance require determine fair value financial nonfinancial asset liability fair value hierarchy establish guidance describe level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation follow table summarize asset liability record fair value respective fair value classification level input fair value hierarchy define thousand december december level level level total level level level total asset debt security treasury security government sponsor entity debt security municipal debt security corporate debt security residential mortgagebacked security student loanbacke security debt security total debt security equity security derivative liabilitie derivative table content gilead sciences inc note consolidated financial statementscontinue marketable security measure fair value level input primarily comprise government sponsor corporate debt security company review trading activity pricing investment measurement date sufficient quote price identical security available company use market pricing observable market input similar security obtain party datum provider input represent quote price similar asset active market input derive observable market datum approach result classification security level fair value hierarchy follow table reconciliation marketable security measure fair value significant unobservable input level thousands year end december balance beginning period total realize unrealized gain loss include interest income net comprehensive income net sale marketable security transfer level balance end period total loss include interest income net attributable change unrealized loss relate asset hold reporting date marketable security measure fair value level input substantially comprise auction rate security availableforsale investment portfolio underlie asset auction rate security comprise student loan auction rate security typically measure level input failure auction lack market activity liquidity experience begin require security measure level input fair value auction rate security determine discount cash flow model consider project cash flow issue trust underlie collateral expect yield project cash flow estimate base underlying loan principal bond outstanding payout formula weightedaverage life cash flow project consider collateral composition security relate historical project prepayment underlie student loan weightedaverage expect life year discount rate discount cash flow model base market condition comparable similar term assetbacke security fix income security adjust illiquidity discount result annual discount rate auction rate security reset seven day maturity date range annual interest rate range december auction rate security continue earn interest april fasb issue additional guidance estimate fair value volume level activity asset liability significantly decrease relation normal market activity asset liability applicable valuation auction rate security hold active market december auction rate security record longterm marketable security consolidate balance sheet december continue fail auction lack market activity liquidity believe otherthantemporary impairment security december intend sell security likely require sell security recovery amortize cost basis table content gilead sciences inc note consolidated financial statementscontinue availableforsale security follow table summary availableforsale debt equity security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security generally base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december debt security treasury security government sponsor entity debt security municipal debt security corporate debt security residential mortgagebacked security student loanbacke security debt security total debt security equity security total december debt security treasury security government sponsor entity debt security municipal debt security corporate debt security residential mortgagebacked security student loanbacke security debt security total debt security equity security total december debt security consist primarily foreign government agency security assetbacked security follow table summarize classification availableforsale debt equity security consolidate balance sheet thousand december december cash cash equivalent shortterm marketable security longterm marketable security total table content gilead sciences inc note consolidated financial statementscontinue follow table summarize portfolio availableforsale debt security contractual maturity thousand december december amortize amortize cost fair value cost fair value year great year year great year year great year total follow table summarize gross realize gain loss relate sale marketable security thousand year end december gross realize gain sale gross realize loss sale cost security sell determine base specific identification method follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair thousand month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december debt security treasury security government sponsor entity debt security municipal debt security corporate debt security residential mortgagebacked security student loanbacke security debt security total december debt security treasury security government sponsor entity debt security municipal debt security corporate debt security residential mortgagebacked security student loanbacke security debt security total table content gilead sciences inc note consolidated financial statementscontinue december gross unrealized loss primarily result increase yieldtomaturity underlie security approximately respectively total number security unrealize loss position case auction rate security gross unrealized loss cause high discount rate valuation security compare coupon rate security significant fact circumstance arise indicate deterioration creditworthiness issuer security base review security believe otherthantemporary impairment security december intend sell security likely require sell security recovery amortize cost basis derivative financial instrument january adopt guidance derivative instrument prospective basis require enhance qualitative quantitative disclosure enable financial statement user well understand effect derivative hedge entitys financial position financial performance cash flow context entitys risk exposure operate foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro order manage risk relate change foreign currency exchange rate hedge certain foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract foreign currency exchange option contract general market risk foreign currency exchange contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time limit risk counterpartie contract unable perform transact major bank monitor closely context current market condition limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative financial contract trading purpose hedge net investment foreign subsidiary enter foreign currency exchange contract hedge market risk exposure associate foreign currency exchange rate fluctuation certain monetary asset liability foreign subsidiary denominate nonfunctional currency derivative instrument designate hedge record change fair value instrument interest income net consolidated statement income foreign currency exchange contract hedge forecast product sale designate cash flow hedge derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify maturity month inception hedge relationship quarterly basis assess hedge effectiveness prospective basis perform regression analysis take change cash flow underlie contract regress change cash flow hedge instrument assess hedge effectiveness retrospective basis dollar offset approach monthly exclude time value effectiveness testing recognize change time value hedge interest income net effective component hedge record accumulate comprehensive income oci stockholder equity unrealize gain loss hedging instrument hedge forecast transaction occur hedge dedesignate table content gilead sciences inc note consolidated financial statementscontinue unrealized gain loss reclassify product sale majority gain loss relate hedged forecast transaction report accumulate oci december reclassify product sale month notional amount foreign currency exchange forward option contract outstanding billion billion december respectively follow table summarize information fair value derivative instrument consolidate balance sheet december thousand december asset derivative liability derivative location fair value location fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract noncurrent asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate statement income year end december thousands year end december derivative designate hedge net loss recognize oci effective portion net gain reclassify accumulate oci product sale effective portion net loss recognize interest income net ineffective portion amount exclude effectiveness testing derivative designate hedge net loss recognize interest income net acquisition cv therapeutics inc january adopt guidance recognize measure asset acquire liability assume noncontrolle interest acquiree business combination guidance provide clarification recognize measure goodwill acquire business combination require iprd table content gilead sciences inc note consolidated financial statementscontinue capitalize fair value intangible asset time acquisition require acquisitionrelate expense restructure cost recognize separately business combination expand definition constitute business require acquirer disclose information user need evaluate understand financial effect business combination adopt provision guidance prospective basis apply acquisition cv therapeutic discuss april acquire cv therapeutic cash tender offer term agreement plan merger enter march cv therapeutic publiclyheld biopharmaceutical company base palo alto california primarily focus discovery development commercialization small molecule drug treatment cardiovascular metabolic pulmonary disease cv therapeutic market product ranexa treatment chronic angina lexiscan injection use pharmacologic stress agent radionuclide mpi patient unable undergo adequate exercise stress cv therapeutic product candidate clinical development treatment cardiovascular metabolic pulmonary disease believe acquisition provide opportunity expand cardiovascular therapeutic area cv therapeutic acquisition account business combination result operation cv therapeutic april include consolidated statement income significant acquisition date determine april date acquire approximately outstanding share common stock cv therapeutic obtain effective control company acquisition complete day later april time cv therapeutic whollyowne subsidiary aggregate consideration transfer acquire cv therapeutic billion consist cash pay common stock equity instrument prior close billion fair value vest stock option assume million accordance merger agreement number gilead stock option restrict stock unit assume cv therapeutic stock option restrict stock unit convert determine base option conversion ratio conversion ratio calculate taking share acquisition price divide average closing price common stock consecutive trading day immediately precede include closing date april share fair value stock option assume calculate blackschole valuation model follow assumption market price share closing price common stock acquisition date expect term range year riskfree interest rate range expect volatility range dividend yield fair value restrict stock unit assume calculated acquisitiondate closing price share common stock include fair value vest stock option assume million consideration transfer acquisition vest restrict stock unit assume estimate fair value unvested stock option restrict stock unit assume million include consideration transfer recognize stockbased compensation expense remain future vest period award table content gilead sciences inc note consolidated financial statementscontinue follow table summarize asset acquire liability assume april thousand intangible assetsmarketed product intangible assetsiprd goodwill defer tax asset defer tax liability assetsliabilitie cash cash equivalent marketable security account receivable inventory prepaid current asset property plant equipment asset account payable accrue current liability convertible senior note liability total net liability total consideration transfer fourth quarter record balance sheet reclassification reduce intangible asset relate iprd million reduce defer tax liability million increase goodwill million reclassification result discovery information affect initial valuation certain iprd intangible asset acquire cv therapeutic intangible asset substantial portion asset acquire consist intangible asset relate cv therapeutic market product ranexa lexiscan cv therapeutics iprd project management determine estimate acquisitiondate fair value intangible asset relate market product iprd project million million respectively million intangible asset relate market product million relate ranexa million relate lexiscan determine intangible asset finite useful life amortize respective useful life estimate period associate product patent expire period intangible asset expect contribute future cash flow related product amortize intangible asset relate ranexa estimate useful life amortization rate derive forecast future product sale ranexa amortize intangible asset relate lexiscan estimate useful life straightline basis give current lexiscan revenue consist royalty receive collaboration partner limit ongoing access visibility partner future sale forecast reasonable estimate amortization rate utilize forecasted product sale approach weightedaverage amortization period intangible asset approximately year table content gilead sciences inc note consolidated financial statementscontinue million intangible asset relate iprd project million relate gs cvt product candidate phase clinical study treatment hypertriglyceridemia remain balance intangible asset relate iprd project represent process project single project comprise significant portion total value intangible asset relate iprd project consider indefinite live completion abandonment associate rd effort period asset consider indefinitelive amortize test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value iprd project respective carrying amount development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time estimate fair value intangible asset relate market product iprd project determine income approach discount expect future cash flow present value estimate fair value intangible asset present value discount rate base estimate weightedaverage cost capital company profile substantially similar cv therapeutic comparable estimate internal rate return cv therapeutic operation represent rate market participant use value intangible asset intangible asset relate iprd project compensate differ phase development project probabilityadjuste estimation expect future cash flow associate project determine present value expect future cash flow discount rate project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market defer tax asset defer tax liability million defer tax asset result acquisition primarily related federal state net operating loss tax credit carryforward million defer tax liability result acquisition primarily relate difference book basis tax basis intangible asset relate market product iprd project conclude likely realize benefit defer tax asset relate certain state net operating loss carryforward result valuation allowance million record related defer tax asset presentation purpose million defer tax liability noncurrent nature net noncurrent defer tax asset consolidate balance sheet convertible senior note result acquisition assume convertible note cv therapeutic consist senior subordinate convertible note senior subordinated convertible note senior subordinated convertible debenture convertible note recognize fair value acquisition date offer repurchase convertible note consideration par value plus accrue interest require term respective convertible note agreement follow occurrence change control fundamental change define agreement december substantially convertible note extinguish table content gilead sciences inc note consolidated financial statementscontinue goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result acquisition management believe goodwill mainly represent synergies economy scale expect combine operation cv therapeutic goodwill expect deductible income tax purpose record goodwill intangible asset consolidated balance sheet acquisition date goodwill test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carrying acquisitionrelate transaction cost restructuring expense recognize million acquisitionrelate transaction cost sell general administrative sga expense year end december consist primarily investment banker fee legal accounting cost relate acquisition addition second quarter approve plan realize certain synergy cv therapeutic realign cardiovascular operation eliminate certain redundancy restructuring plan include consolidation realignment cardiovascular rd organization exit certain facility termination certain contractual obligation result restructure plan record million million sga expense rd expense respectively primarily relate employee severance relocation termination benefit lease termination cost facilitiesrelate expense expect incur additional million bring total incur connection significant activity restructuring plan approximately million employee severance relocation termination benefit million facilitiesrelate expense follow table summarize restructure liability accrue change amount period thousand employee severance facility termination relate benefit cost balance december cost incur period cost pay settle period balance december pro forma information follow unaudited pro forma information present combine result operation gilead cv therapeutic acquisition cv therapeutic complete january respectively adjustment effect pro forma event directly attributable acquisition unaudite pro forma result reflect operating efficiency potential cost saving result consolidation operation gilead cv therapeutic accordingly unaudite pro forma result present illustrative purpose intend represent indicative actual result operation combine company achieve acquisition occur begin period present intended represent indicative future result operation table content gilead sciences inc note consolidated financial statementscontinue follow table summarize unaudited pro forma result operation thousands year end december total revenue net income attributable gilead navita asset llc execute asset purchase agreement navita asset llc navita acquire asset relate cicletanine business acquire exclusive right regulatory data filing development cicletanine monotherapy pah indication united states evaluate cicletanine currently phase clinical trial potential treatment pah aggregate consideration transfer acquisition million consist primarily cash pay addition navita entitle potential additional purchase consideration include payment contingent future achievement certain development regulatory milestone amount record related contingency resolve consideration transfer allocate iprd represent purchase iprd program cicletanine reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement income nycome limited september complete acquisition nycome limited nycome whollyowne irish subsidiary germanybase pharmaceutical company nycome gmbh nycome facility locate cork ireland conduct manufacturing tablete operation nycome gmbh transfer certain manufacturing operation dublin ireland area site facility utilize site primarily solid dose tablet manufacturing exist future product product packaging nycome acquisition account business combination result operation nycome acquisition date include consolidated statement income aggregate consideration transfer nycomed common stock million consist cash pay closing million estimate direct transaction cost million employeerelate severance cost million employeerelate severance cost capitalize purchase price establish workforce reduction plan acquisition transaction cost fully pay consideration transfer allocate primarily property plant equipment million remain balance allocate net work capital connection transfer certain manufacturing operation dublin ireland area site cork facility finalize personnel plan respect dublin employee recognize onetime termination benefit million fourth quarter table content gilead sciences inc note consolidated financial statementscontinue inventory inventory summarize follow thousand december raw material work process finish good total inventory december joint venture form gilead bms note include consolidated financial statement hold million million inventory respectively efavirenz active pharmaceutical ingredient purchase bms bmss estimate net sell price efavirenz property plant equipment property plant equipment summarize follow thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress subtotal accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total january complete purchase office building approximately acre land locate foster city california aggregate purchase price million base estimate relative fair value purchase price allocate primarily land million building million land improvement million office furniture equipment million table content gilead sciences inc note consolidated financial statementscontinue intangible asset follow table summarize carry intangible asset thousand december goodwill finite live intangible asset indefinite live intangible asset total follow table summarize change carry goodwill thousand balance december goodwill result acquisition cv therapeutics balance december follow table summarize finitelive intangible asset thousand december december gross gross carrying accumulate carry accumulate amortization amortization intangible assetranexa intangible assetlexiscan total amortization expense relate intangible asset million year end december record primarily cost good sell consolidated statement income amortization expense relate intangible asset million million year end december respectively record primarily sga expense consolidate statement income december estimate future amortization expense associate intangible asset succeed fiscal year follow thousands fiscal year total december indefinitelive intangible asset million relate purchase iprd acquisition cv therapeutic table content gilead sciences inc note consolidated financial statementscontinue collaborative arrangement result enter strategic collaboration time time hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure base applicable guidance december determine certain investee company variable interest entity respect joint venture bms primary beneficiary consolidate investee bristolmyers squibb company north america december enter collaboration bms united states develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz sell atripla collaboration structure joint venture operate limited liability company name bristol myers squibb gilead sciences llc consolidate ownership interest joint venture share product revenue cost reflect respective economic interest bms base proportion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bmss respective economic interest joint venture vary annually share marketing sale effort bms party obligate provide equivalent sale force effort minimum number year responsible accounting financial reporting tax reporting product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value july joint venture receive approval fda sell atripla united states september bms amend joint venture collaboration agreement allow joint venture sell atripla canada october joint venture receive approval health canada sell atripla canada december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price efavirenz market amount include inventory consolidate balance sheet december total asset hold joint venture billion billion respectively consist primarily cash cash equivalent account receivable include intercompany receivables gilead inventory december total liability hold joint venture billion million respectively consist primarily account payable include intercompany payable gilead accrue expense asset liability amount reflect impact intercompany elimination include consolidated balance sheet primary beneficiary joint venture legal structure joint venture limit recourse creditor general credit asset europe december gilead sciences limited gsl whollyowne subsidiary ireland bms enter collaboration arrangement commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory copromote atripla bms responsible accounting financial reporting tax reporting collaboration december table content gilead sciences inc note consolidated financial statementscontinue european commission approve atripla sale european union december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity share marketing sale effort bm major market country party agree provide equivalent sale force effort revenue cost sharing base relative ratio respective net selling price truvada efavirenz pari gmbh result acquisition corus pharma inc corus august assume right february development agreement corus pari gmbh pari development cayston development inhalation delivery device product term agreement obligate pay pari service render subject achievement specific milestone obligate pay certain milestone payment pari addition royalty payment base net sale cayston agreement provide right reduce royalty rate payable pari november pay pari million reduce royalty rate agreement cayston approve commercialization december record payment rd expense consolidate statement income april pursuant february development agreement enter commercialization agreement pari provide supply manufacture inhalation delivery device accessory use cayston term agreement obligate pay royalty future net sale product pursuant development agreement february receive marketing approval fda cayston treatment improve respiratory symptom cf patient pseudomona aeruginosa p aeruginosa cayston conditionally approve europe canada september lg life sciences ltd november enter license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitor treatment fibrotic disease agreement grant commercialization right lglss caspase inhibitor include gs lb term agreement license worldwide exception korea china india lgls retain right lgls retain right develop commercialize caspase inhibitor ophthalmic topical use worldwide accordance term agreement pay million upfront license fee record rd expense consolidate statement income future alternative use technology agreement obligate fund collaborative research program year identify potential caspase inhibitor drug candidate addition obligate additional milestone payment million achievement certain development regulatory commercial objective obligate pay royalty future net sale product develop approve relation collaboration parion sciences inc august enter research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel enac inhibitor treatment pulmonary disease agreement grant worldwide commercialization right gs table content gilead sciences inc note consolidated financial statementscontinue p enac inhibitor discover parion treatment pulmonary disease include cf chronic obstructive pulmonary disease noncf bronchiectasis accordance term agreement pay million upfront license fee record rd expense consolidate statement income future alternative use technology million investment parion form convertible debt record noncurrent asset consolidate balance sheet collaboration agreement lead development commercialization activity provide funding time equivalent employee certain research activity addition obligate additional payment achievement certain milestone pay royalty future net sale product develop approve relation collaboration roche september enter development license agreement agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost november enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year b million worldwide net sale calendar year c worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement record total million million million tamiflu royalty respectively result acquisition cv therapeutics april assume right agreement cv therapeutic roche exclusive worldwide license ranexa license agreement pay initial license fee obligate certain payment roche receipt second product approval ranexa follow major market country france germany italy united states united kingdom january receive fda approval ranexa treatment chronic angina pay million roche accordance agreement july receive marketing authorization european medicine agency emea ranexa treatment chronic angina european union member state pay million roche relate approval capitalize noncurrent asset consolidated balance sheet amortize useful patent life approximately year expire september table content gilead sciences inc note consolidated financial statementscontinue june enter amendment agreement roche relate ranexa amendment provide exclusive worldwide commercial right ranexa potential indication human term amendment upfront payment roche obligate royalty payment roche worldwide net product sale license product addition obligate additional milestone payment achievement certain regulatory approval japan tobacco inc march japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor know gs country world exclude japan japan tobacco retain right term agreement incur license fee million include rd expense future alternative use technology march record million rd expense relate milestone incur result dose patient phase clinical study july record million rd expense relate milestone pay related dose patient phase clinical study obligate additional payment achievement milestone pay royalty future product sale arise collaboration glaxosmithkline inc april grant gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan south korea taiwan gsk responsibility development commercialization hepsera territory term agreement receive upfront license payment million receive aggregate million milestone payment relate commercial approval hepsera country receive aggregate million milestone payment gsk achievement gsk consecutive quarter hepsera gross sale exceed million achievement certain drug status china upfront license fee milestone payment record defer revenue total million million amortize contract revenue respectively quarter terminate supply agreement gsk allow gsk assume manufacture supply obligation hepsera use gsk territory result termination supply agreement recognize remain million balance defer revenue contract revenue march term agreement gsk require pay royalty net sale gsk generate sale hepsera epivirhbvzeffix gsk hepatitis product gsk territory record million million million royalty revenue respectively november enter agreement gsk commercialize viread treatment chronic hepatitis b country asia agreement retain exclusive right commercialization viread chronic hepatitis b hong kong singapore south korea taiwan china gsk exclusive commercialization right viread chronic hepatitis b company pay royalty sale viread chronic hepatitis b respective asian territory result acquisition myogen inc myogen november assume right march license distribution supply agreement myogen gsk term license agreement sublicense gsk exclusive right market ambrisentan active pharmaceutical ingredient letairis market volibris territory outside united states table content gilead sciences inc note consolidated financial statementscontinue pah territory outside united states receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million addition receive royalty base net sale volibris gsk territory gsk option negotiate exclusive sublicense additional therapeutic use volibris gsk territory term license agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis volibris united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development receive milestone payment million gsk validation emea marketing authorization application volibris receive million milestone payment relate european commission marketing authorization approval volibris milestone upfront license payment record defer revenue amortize contract revenue remain period performance obligation agreement approximately year amortize million million million contract revenue respectively menarini international operation luxembourg sa result acquisition cv therapeutics april assume right september license agreement cv therapeutics menarini grant menarini exclusive right ranexa european union specify country consideration include upfront payment million license territory encompass country include member states european union russia member states commonwealth independent state select country central south america term agreement expire countrybycountry basis later occur year commercial sale date ranexa country expiration valid claim license patent cover ranolazine country addition menarini additional payment investment commercial development milestone promotional detail commitment commercial milestone primarily relate achievement certain sale level development milestone relate approval ranexa europe certain additional indication jointly develop agreement provide mechanism party collaborate share cost joint development program ranexa menarini elect participate entitle receive royalty sale ranexa territory cover agreement astella llc astella pharma inc astellas applicable result acquisition cv therapeutics april assume right july collaboration agreement cv therapeutic astella llc develop market second generation pharmacologic mpi stress agent agreement astella receive exclusive north american right lexiscan backup compound april receive fda approval lexiscan use pharmacologic stress agent mpi study patient unable undergo adequate exercise stress term agreement product market astella launch june united states year end december recognize million royalty revenue astella relate sale lexiscan agreement astella pharma inc relate right market ambisome term agreement astella responsible promotion ambisome united states canada exclusive marketing right ambisome rest world subject table content gilead sciences inc note consolidated financial statementscontinue obligation pay royalty astellas connection sale significant market asia receive royalty astellas sale ambisome unites states canada connection agreement record royalty revenue million million million respectively tibotec pharmaceutical july enter license collaboration agreement tibotec pharmaceutical tibotec whollyowne subsidiary johnson johnson develop commercialize fixeddose combination truvada tibotecs nonnucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently phase clinical trial agreement tibotec grant exclusive license combination product administration adult daily oral dosage form worldwide exclude develop world country japan party restrict combine drug product drug accordance term agreement reimburse million approximately million development cost incur tibotec tmc december require use commercially reasonable effort develop formulate combination product include completion bioequivalence study year end december record million reimbursable rd expense incur tibotec development tmc tibotec require use commercially reasonable effort develop tmc obtain approval united states europe manufacture combination product assume lead role registration distribution subject regulatory approval commercialization combination product license country tibotec right detail combination product license country option request distributor combination product limited number country price combination product expect sum price truvada price tmc purchase separately expect recognize product sale revenue future sale combination product approve cost tmc purchase tibotec combination product approximate market price tmc specified percentage thirty percent longterm obligation convertible senior note april issue million principal convertible senior note million principal convertible senior note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note note convertible common stock base initial conversion rate share principal note represent initial conversion price approximately share note convertible common stock base initial conversion rate share principal note represent initial conversion price approximately share note convert subject adjustment follow circumstance calendar quarter begin september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder table content gilead sciences inc note consolidated financial statementscontinue receive cash equal less principal note ii conversion value note conversion value exceed deliver option cash common stock combination cash common stock conversion value excess note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal note plus accrue unpaid interest thereon result adopt guidance relate note bifurcated conversion option note debt instrument classified conversion option equity accrete result debt discount interest expense follow table summarize information equity liability component note thousand december carry equity component net carrying liability component unamortized discount liability component total interest expense recognize note million million million year end december respectively december effective interest rate liability component note respectively note convert december ifconverte value exceed principal amount note note million million respectively concurrent issuance note purchase convertible note hedge private transaction cost million cover subject customary antidilution adjustment million share common stock strike price correspond initial conversion price note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction cash share common stock combination cash common stock option excess market price common stock strike price convertible note hedge convertible note hedge terminate maturity relate note relate note remain outstanding conversion sell warrant acquire million share common stock subject customary antidilution adjustment private transaction receive net proceed million market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price maximum number share common stock issue choose net share settle warrant million share underlie share reserve potential future issuance warrant strike price share warrant expire share warrant expire exercisable respective expiration date take convertible note hedge warrant intend reduce potential dilution future conversion note effectively increase initial conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity choice settle convertible note hedge warrant cash share stock contract meet applicable criterion equity classification cost convertible table content gilead sciences inc note consolidated financial statementscontinue note hedge net proceed sale warrant classify stockholder equity addition contract classify stockholder equity index common stock account derivative record defer tax asset million apic effect future tax benefit relate convertible note hedge contemporaneously close sale note portion net proceed note issuance proceed warrant transaction repurchase million share common stock million stock repurchase program term note agreement require comply certain covenant december compliance covenant result cv therapeutic acquisition assume certain convertible note cv therapeutic note december substantially convertible note extinguish credit facility december enter agreement syndicate bank year million senior credit facility million facility consist uncollateralized million term loan enter gilead biopharmaceutics ireland corporation gbic whollyowne irish subsidiary uncollateralize million revolve credit facility enter parent company gilead sciences inc proceed term loan gbic december facilitate cash dividend distribution million parent company repatriation qualified foreign earning provision american job creation act ajca year end december repay million represent remain amount term loan time term loan terminate term revolve credit facility enter december interest accrue payable rate libor plus tiere contractual rate basis point payable quarterly arrear parent company prepay outstanding borrowing accrue interest prepay principal time penalty premium outstanding interest principal december payable demand capacity revolve credit facility increase maximum million term loan repay ability irrevocably cancel unutilized portion revolve credit facility proceed obtain revolve credit facility expect work capital capital expenditure general corporate purpose include issuance letter credit million whollyowne subsidiary guarantor december gbic enter amend restate credit agreement supersede exist revolve credit agreement syndicate bank increase credit facility billion credit agreement include subfacility swingline loan letter credit loan credit agreement bear interest libor plus margin range basis point basis point base rate describe credit agreement reduce commitment prepay loan credit agreement penalty subject certain condition credit agreement terminate amount owe thereunder shall payable december connection credit agreement parent company enter agreement guarantee obligation gbic credit agreement april connection acquisition cv therapeutic borrow million credit agreement partially fund acquisition december repay million credit agreement expect use table content gilead sciences inc note consolidated financial statementscontinue proceed loan credit agreement work capital requirement general corporate purpose december million letter credit outstanding credit agreement require comply certain covenant credit agreement december compliance covenant commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility lease facility foster city palo alto san dimas california durham north carolina boulder westminster colorado seattle washington dublin area ireland london area united kingdom operate lease sale marketing administrative facilities europe canada australia lease expire date lease ireland united kingdom year respectively rent subject increase fifth anniversary respective commencement date facility lease option renew lease corporate aircraft vary term renewal option expiration lease term lease expense operating lease approximately million million million year end december respectively aggregate noncancelable future minimum rental payment operating lease follow thousand legal proceeding united states district court northern district california execute order dismiss entirety prejudice fourth consolidated amend complaint associate putative class action lawsuit company current executivesour chairman chief executive officer president chief operating officer executive vice president operation executive vice president research development chief scientific officer senior vice president manufacture senior vice president researchallege defendant violate federal security law specifically section b securities exchange act amend rule b promulgate sec make certain allege false misleading statement plaintiff appeal dismissal august united states court appeals ninth circuit reverse district court decision remand case district court february file petition writ certiorari supreme court united states request court review judgment court appeal april supreme court deny petition case continue district court february file motion dismiss fourth consolidated amend complaint alternative ground june district court grant deny motion dismiss give plaintiff leave amend complaint july plaintiff file fifth consolidated amend complaint file motion dismiss fifth consolidated amend complaint district court hear october order date october court grant deny motion table content gilead sciences inc note consolidated financial statementscontinue dismiss respect section b claim court deny motion gilead individual defendant court grant motion individual defendant section claim court deny motion individual defendant defendant remain case november file answer fifth consolidated amend complaint court schedule case management conference possible predict outcome case amount accrue relate outcome case august receive subpoena office inspector general department health human service request document development marketing sale ranexa cooperate continue cooperate relate governmental inquiry possible predict outcome inquiry amount accrue relate outcome inquiry party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient billion billion million year end december respectively terminate prior agreement purchase aircraft construct delivery stockholder equity stock repurchase programs march board directors board authorize program repurchase common stock billion twoyear period open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement april repurchase retire share common stock share aggregate purchase price million june repurchase retire aggregate share common stock average purchase price share aggregate purchase price million stock repurchase program expire march october board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement repurchase plan expire december repurchase retire share common stock share aggregate million billion stock repurchase program table content gilead sciences inc note consolidated financial statementscontinue february enter accelerate share repurchase agreement financial institution repurchase million common stock accelerate basis term accelerate share repurchase agreement pay million financial institution settle initial purchase transaction receive share common stock price share june maturity agreement accordance share delivery provision agreement receive additional share common stock base average daily volume weight average price common stock specify period predetermined discount share result average purchase price common stock accelerate share repurchase share account accelerate share repurchase separate transaction share common stock acquire treasury stock transaction record transaction date b forward contract index common stock account share receive repurchase common stock retire share immediately net income share purpose additional share receive maturity contract june record stockholder equity determine forward contract index common stock meet applicable criterion equity classification contract account derivative october enter accelerate share repurchase agreement financial institution repurchase million common stock accelerate basis term accelerate share repurchase agreement pay million settle initial purchase transaction receive share common stock initial price share march termination agreement accordance share delivery provision agreement receive additional share common stock base average daily volume weightedaverage price common stock specify period predetermined discount share result total number share repurchase retire accelerate share repurchase agreement share average purchase price share accounting accelerate share repurchase consistent previous accelerated share repurchase addition common stock repurchase accelerated share repurchase transaction repurchase retire share common stock average purchase price share aggregate purchase price million open market transaction addition additional share receive accelerated share repurchase agreement complete march repurchase retire share common stock average purchase price share aggregate purchase price million open market transaction december complete share repurchase billion stock repurchase program use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning result stock repurchase reduce common stock apic aggregate million charge million retain earning result stock repurchase reduce common stock apic aggregate million charge billion retain earning result stock repurchase reduce common stock apic aggregate million charge million retain earning january board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan table content gilead sciences inc note consolidated financial statementscontinue privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement repurchase plan expire january prefer stock share authorize preferred stock issuable series board authorize determine designation power preference right series designate share series junior participate prefer stock potential issuance november right agreement bny mellon investor service llc know chasemellon shareholder services llc amend right plan prefer stock outstanding december right plan right plan provide distribution prefer stock purchase right dividend share common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade common stock october october board approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october amendment clarify amendment enter connection increase designate number share series junior participate prefer stock potential issuance right plan stock option plan stockholder approve adopt gilead sciences inc equity incentive plan plan stock option nexstar pharmaceuticals inc nexstar triangle pharmaceuticals inc triangle corus myogen cv therapeutics stock option plan assume result acquisition nexstar triangle corus myogen cv therapeutic convert option purchase common stock effective closing respective acquisition plan broad base incentive plan allow award grant employee director consultant plan provide option grant designate nonqualifie incentive stock option prior january grant non qualified incentive stock option stock option grant january nonqualified stock option plan employee stock option generally vest year exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share stockholder approve amendment plan increase number share authorize issuance plan share common stock table content gilead sciences inc note consolidated financial statementscontinue connection acquisition cv therapeutic assume cv therapeutics equity incentive plan amend restate nonemployee director stock option plan amend restate equity incentive plan amend restate nonstatutory incentive plan amend restate employee commencement incentive plan amend restate collectively cv therapeutic plan majority option issue outstanding cv therapeutic plan april convert option purchase approximately million share common stock remain subject original term condition share available future grant cv therapeutic plan december total share common stock authorize grant share remain available future grant plan follow table summarize activity stock option plan option grant present table exercise price fair value underlie common stock grant date share thousand year end december weight weight weight average average average share exercise price share exercise price share exercise price outstanding beginning year grant assume forfeited expired exercise outstanding end year exercisable end year weightedaverage grant date fair value option grant year total intrinsic value option exercise year end december million million million respectively total fair value stock option vest year end december million million million respectively december number option outstanding expect vest net estimate future option forfeiture weightedaverage exercise price share aggregate intrinsic value million weightedaverage remain contractual life year aggregate intrinsic value stock option outstanding stock option exercisable december billion billion respectively december weightedaverage remain contractual life option outstanding option exercisable year respectively december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year table content gilead sciences inc note consolidated financial statementscontinue performance share restrict stock award january grant performancebase share award performance share plan award divide tranche vest performance measurement purpose subject achievement specify market performance goal relative predetermine peer group awards vest threeyear period actual number share common stock ultimately issue calculate multiplying number performance share payout percentage range performance share vest committee subcommittee board determine achieve specified market performance goal fair value performance share estimate grant date monte carlo valuation methodology stockbase compensation expense performance share recognize requisite service period straightline expense attribution approach reduce forfeiture weightedaverage grant date fair value performance share share january grant performancebase share award performance share performance share respectively term substantially similar performance share single threeyear performance measurement vest period performance share performance share weightedaverage grant date fair value performance share performance share share respectively performance share recognize million million million stockbase compensation expense respectively relate performance share grant timebase restrict stock award employee plan award vest annually fiveyear period recognize million stockbase compensation expense relate timebased award grant performancebase restrict stock award certain employee plan vest award subject achievement specify performance goal number award issue date significant employee stock purchase plan employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer twoyear lookback feature automatic reset feature provide offer period reset new lower price offering offer price new offering period current offering period espp purchase settle common stock espps previously authorize available pool share share issue espp million total share common stock reserve issuance espp share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year table content gilead sciences inc note consolidated financial statementscontinue stockbased compensation follow table summarize stockbase compensation expense include consolidated statement income thousands year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense include net income year end december capitalize million million million stockbase compensation cost inventory respectively stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach nonveste stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic table content gilead sciences inc note consolidated financial statementscontinue valuation assumption fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout comprehensive income loss comprehensive income loss comprise net income certain change stockholder equity exclude net income change fair value outstanding effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability table content gilead sciences inc note consolidated financial statementscontinue follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealized gain loss relate availableforsale security net tax impact respectively net unrealized gain loss relate cash flow hedge net tax impact respectively reclassification adjustment relate cash flow hedge net tax impact respectively comprehensive income loss balance accumulate comprehensive income loss net taxis report consolidated balance sheet consist follow component thousand december net unrealized gain loss availableforsale security net unrealize gain loss cash flow hedge cumulative foreign currency translation adjustment accumulate comprehensive income loss disclosure segment enterprise related information operate business segment primarily focus development commercialization human therapeutic life threaten disease product include segment major product truvada atripla viread hepsera ambisome account substantially total product sale year end december similar economic characteristic include nature product production process type customer distribution method regulatory environment table content gilead sciences inc note consolidated financial statementscontinue product sale consist follow thousands year end december antiviral product truvada atripla viread hepsera emtriva total antiviral product ambisome letairis ranexa total product sale follow table summarize total revenue external customer collaboration partner geographic region thousand product sale productrelate contract revenue attribute country base shipto location royalty nonproduct relate contract revenue attribute country base location collaboration partner year end december united states outside united states france spain united kingdom italy germany switzerland european country country total revenue outside united states total revenue december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment table content gilead sciences inc note consolidated financial statementscontinue follow table summarize revenue customer individually account total revenue total revenue year end december cardinal health inc mckesson corp amerisourcebergen corp income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income billion billion billion year end december respectively cumulative unremitted foreign earning consider permanently invest outside united states taxis provide approximately billion billion december respectively residual tax liability amount remit approximately billion billion december respectively difference provision income taxis compute apply federal statutory income tax rate income provision income taxis follow thousands year end december income provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation provision income taxis table content gilead sciences inc note consolidated financial statementscontinue deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousand defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward capitalize intangible net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance increase decrease million million million year end december respectively april acquisition cv therapeutic establish valuation allowance million defer tax asset relate california state net operating loss carryforward december integration cv therapeutic conclude likely realize benefit defer tax asset relate certain state net operating loss carryforward release related valuation allowance result income tax benefit approximately million december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss tax credit carryforward start expire respectively utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss nol credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onward certain acquire entity statute limitation open year inception utilization nol credit carry prior year california income tax purpose statute limitation remain open year table content gilead sciences inc note consolidated financial statementscontinue income tax return audit federal state foreign tax authority currently examination internal revenue service irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position december total federal state foreign unrecognized tax benefit million million respectively include interest million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income reach agreement irs issue relate examination federal income tax return amend california income tax return base resolution certain tax position irs result reduce unrecognized tax benefit million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority follow rollforward total gross unrecognized tax benefit liability year end december thousands balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period defer compensation plan maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match contribute employee contribution annual maximum match total matching contribution expense table content gilead sciences inc note consolidated financial statementscontinue gilead plan year end december million million million respectively maintain deferred compensation plan director key employee defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer senior grade level employee contribute annual salary annual bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share common stock fractional share pay cash establish plan administrator december phantom share outstanding participant elect distribution date available plan receive defer compensation payment subsequent event january board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement repurchase plan expire january february receive marketing approval fda cayston treatment improve respiratory symptom cf patient p aeruginosa table content gilead sciences inc note consolidated financial statementscontinue quarterly result operation unaudite follow amount thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute second quarter recognize million charge purchase iprd associate acquisition asset navita relate cicletanine business january adopt guidance note note retrospective basis guidance require bifurcate conversion option debt instrument classify conversion option equity accrete result discount debt additional interest expense expect life debt note january adopt guidance joint venture bms retrospective basis result adopt guidance present noncontrolle interest consolidate statement income net loss attributable noncontrolle interest component consolidate net income retrospective basis note table content gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback valuation allowance defer tax asset include million million december respectively relate acquisition table content